



CURRICULUM VITAE
EDITH PETERSON MITCHELL, MD, MACP, FCPP, FRCP

Address:

Sidney Kimmel Cancer Center at Jefferson
Bluemle Life Sciences Building
233 South 10th Street; Suite 502
Philadelphia, PA 19107
Phone: 215-955-4652
Fax: 215-503-4103

Marital Status:

Widow – Delmar K. Mitchell (d. 2021)
Daughters:
Dale Edith Mitchell-Hobbs
DeAnna Peterson Mitchell

Education:

High School: Carver High School (Brownsville, TN), Diploma - 1965, Class Valedictorian

College:
1965-1969 Tennessee State University, Bachelor of Science in Biochemistry, “With Distinction”

Medical School:
1971-1972 Washington University, School of Medicine
1972-1974 Medical College of Virginia, Three-Year Accelerated Program
May 1974 Graduated, Medical College of Virginia, MD Degree

Present Academic and Hospital Appointments:

1977-1978 Chief, Resident and Instructor in Medicine, Meharry Medical College
1978-1984 Physician, United States Air Force, United States Department of Defense
1978-1982 Uniformed Services Instructor, University of the Health Sciences
1984-1985 Chief, Solid Tumor Service; Director, Medical Education, Department of Medicine, Ellis Fischel State Cancer Center
1985-1992 Associate Professor, School of Medicine, University of Missouri-Columbia
1992-1993 Associate Director, Cancer Clinical Diagnostics, Centocor, Inc.
1993-1995 Senior Director, Clinical Research, U.S. Bioscience, Inc.
1995-Present Clinical Professor of Medicine and Medical Oncology, Sidney Kimmel Medical College at Jefferson
2006-Present Associate Director for Diversity and Minority Programs, Sidney Kimmel Cancer Center at Thomas Jefferson University

Professional Training:

1974-1975 Internship, Internal Medicine, Meharry Medical College
1975-1977 Residency, Internal Medicine, Meharry Medical College
1979-1981 Fellowship, Medical Oncology, Georgetown University

2017 – 2021 Achievements and Honors:

- American Society of Radiation Oncology Honorary Award for achievements in Combined Modality Therapy
- Pennsylvania House and Senate Award for achievement in Cancer Prevention and Treatment
- Member, National Cancer Institute Moonshot Blue Ribbon Panel
- Plant a Seed Mentoring Program in science for more than 500 minority elementary and high school students
- Principal Investigator, ECOG-ACRIN Cancer Research Group
- Urban League Whitney Young Community Engagement Award
- National Medical Association Cobb Institute Achievement Award
- National Medical Association Women in Medicine Achievement Award
- Member, National Institutes of Health Council of Councils
- Member, National Cancer Institute Clinical Trials and Translational Research Advisory Committee
- Member, American Society of Clinical Oncology Disparities Advisory Committee
- Director, Accreditation Council for Graduate Medical Education
- Board of Trustees, Tennessee State University
- Community Advisory Board, Geisinger Commonwealth School of Medicine
- Board of Directors, Patient Advocacy Foundation
- Advisor, Student National Medical Association
- Participant, National Institutes of Health “All of Us” Program
- Member, President’s Cancer Panel

Honors and Awards:

- | | |
|-----------|---|
| 1967-1968 | Who’s Who In American Colleges and Universities |
| 1967 | Alpha Kappa MU Honor Society |
| 1968 | Beta Kappa Chi Scientific Honor Society |
| 1969 | Graduation – With Distinction |
| 1974 | Three-year Accelerated Medical School Graduate |
| 1983 | Fellowship, American College of Physicians |
| 1984 | Outstanding Young Women of America |
| 1985 | Missouri-Assembly-Community Service Award |
| 1989 | Sigma XI |
| 1990 | Malcolm Grow Award for Society of Air Force Physicians |
| 1991 | Faculty-Alumni Award, University of Missouri-Columbia MU Alumni Association |
| 1994 | Distinguished Service Award, Air National Guard |
| 1995 | State Air Surgeon, Missouri Air National Guard |
| 2007 | America’s Top Oncologists |
| 2008 | Tree of Life Award presented by The Wellness of You Foundation |
| 2009 | Cancer Control Award presented by The American Cancer Society |
| 2009 | In The Looking Glass Award presented by The Living Through Cancer Foundation |
| 2010 | Physician of the Year presented by CancerCare |
| 2011 | Physician of the Year, Philadelphia County Society of Medicine |
| 2012 | Quality of Life Award presented by Bebashi Transition of Hope |
| 2012 | Susan G. Komen Partner in Health Equality |
| 2013 | Lifetime Achievement Award presented by the Alpha Kappa Alpha Sorority, Inc., North Atlantic Region |

2013	Induction – National Black Colleges and Universities Alumni Hall of Fame
2015	Vivian and Meyer P. Potamkin Foundation Award for Breast Cancer Research
2016	Historically Black Colleges and Universities Alumna of the Year
2016	“The BIO Award” from Traci’s Bio (Beautiful Inside and Out)
2017	American Society for Radiation Oncology Honorary Member Induction
2017	W. Montague Cobb Lifetime Achievement Award
2017	American Cancer Society Greater Philadelphia Area Volunteer Achievement Award
2017	Medical Society of Eastern Pennsylvania President’s Award
2017	American Cancer Society Greater Philadelphia Area Cancer Control Award
2018	National Cancer Institute Director’s Service Award
2018	Edith P. Wright Breast Cancer Foundation Eydie’s Angels Loving Hands Service Award
2018	Jefferson Health Achievement Award in Medicine
2019	Kappa Alpha Psi, Inc., Distinguished Citizen Award
2019	Philadelphia Life Sciences Ultimate Solution Award
2019	Geisinger Commonwealth School of Medicine Well-Being Award
2019	American College of Physicians Pennsylvania Chapter Women in Medicine Award
2020	United Negro College Fund Honoree
2021	Tennessee State University Black History Month Alumni Honoree
2021	American Association for Cancer Research Scientific Achievement Award - Minorities in Cancer Research Jane Cooke Wright Lectureship Award
2021	<i>Cancer Health Magazine’s Cancer Health 25: Black Lives Matter Award</i>
2022	Thomas Jefferson Provost Award for Service to the Profession
2022	Prevent Cancer Foundation Laurels Award for National Leadership

Board Certification:

1975	Diplomate, National Board of Medical Examiners
1978	Diplomate, American Board of Internal Medicine
1981	Diplomate, American Board of Internal Medicine, Subspecialty Medical Oncology

Licensures:

1976	Tennessee - MB9544
1984	Missouri - R2E29
1995	Pennsylvania - MD-056002-L

Military Experience:

1978-1984	US Air Force Active Duty - Physician
1984-1987	US Air Force Reserve - Physician
1987-2004	Missouri Air National Guard Rank – Brigadier General Air National Guard Assistant to the Command Surgeon, Air Mobility Command
1991	Graduate, Flight Surgeon, US Air Force School of Aerospace Medicine
1995	Graduate, US Air Force Air War College
2004-2005	Assistant Adjutant General and Assistant Commander Joint Forces Command, Missouri National Guard
August 2005	Inactive Reserves
December 2008	– Retired US Air Force

Military Decorations:

1979	Air Force Commendation Medal
1983	Meritorious Service Medal
1984	Air Force Achievement Medal
1993	Air National Guard Humanitarian Award
1995	Meritorious Service Medal
2001	Legion of Merit
2004	Legion of Merit, One Oak Leaf Cluster

Academic Assignments:

1978-1979	General Internist and Chief of Allergy and Immunization, Malcolm Grow USAF Medical Center
1981-1982	Instructor in Medicine, Georgetown University Hospital
1981-1982	Hematologist-Oncologist, Malcolm Grow USAF Medical Center
1982-1984	Chief, Hematologist-Oncology Service David Grant USAF Medical Center, Travis AFB, CA
1984-1985	Clinical Assistant Professor of Medicine, University of Missouri-Columbia
1985-1990	Assistant Professor of Medicine, University of Missouri-Columbia and Assistant to the Dean for Minority Affairs
1989-1992	Director, University of Missouri Sickle Cell Center
1990-1992	Director, University of Missouri Tumor Marker Laboratory
1990-1992	Associate Professor of Medicine, University of Missouri with Tenure
1995-Present	Clinical Professor of Medicine and Medical Oncology, Sidney Kimmel Medical College at Jefferson

Professional Societies and Organizations:

Fellow, American College of Physicians (1983 - 2019)
 Society of Air Force Physicians
 American Society of Clinical Oncology
 American Medical Association
 American Association of Medical Colleges
 National Medical Association (President 2015 - 2016)
 Society of Consultants to the Armed Forces
 Alliance of Air National Guard Flight Surgeons
 Aerospace Medicine Association
 Phi Kappa Phi
 Fellow, College of Physicians of Philadelphia
 Master, American College of Physicians
 Fellow, Royal College of Physicians

National Study Sections, Advisory Panel:

1980	Advisor in Cancer Treatment to the United States Virgin Islands
1985-1989	Study Section: Cancer Clinical Investigation Review Committee, National Cancer Institute
1986-1992	Advisory Board: Missouri Department of Health, Division of Chronic Diseases
1986-1992	Advisory Board: Missouri Minority Health Task Force, Co-Chairperson
1987	Study Section: Biological Response Modifiers Committee, National Cancer Institute
1989 – 1994	Study Section: National Institutes of Health Reviewers Reserve
1991 – 1994	Study Section: Clinical Trials and Cancer Intervention Committee, National Cancer Institute
1992	Study Section: Chemoprevention Committee, National Cancer Institute
1995 – 1998	Study Section: Clinical Research Program Project Grants Review Committee, NCI

1999 Study Section: Progressive Colorectal Review Panel, National Cancer Institute
 2001 – Present Scientific Reviewer: Central Investigational Review Board
 2001 – Present Various Study Sections, National Cancer Institute
 2002 – Present Scientific Reviewer: American College of Radiology
 2013 – Present Member: Clinical Trials and Translational Research Advisory Committee
 2016 – Present Member: National Cancer Institute’s Moonshot Blue Ribbon Panel

Committees:

1982 - 1984 Chairman, Lung Committee, Northern California Oncology Group
 Member, Executive Committee, Northern California Oncology Group
 Member, Gastrointestinal Committee, Northern California Oncology Group
 Member, Human Subjects Review Committee, Northern California Oncology Group
 Member, Tumor Board Hubbard Hospital of Meharry Medical College
 Consultant to Tumor Registry, Georgetown University Hospital and Lombardi Cancer Research Center
 Member, Cancer Committee Malcolm Grow USAF Medical Center
 Member, Tumor-Board Malcolm Grow USAF Medical Center
 Member, Tumor Board David Grant USAF Medical Center
 Member, Tissue and Transfusion Committee, David Grant USAF Medical Center
 1984 - 1989 Member, Lung Committee, Cancer and Leukemia Group B
 1995 - Present Member, GI Committee ECOG
 1995 - Present Member, Underserved Populations Committee ECOG, (Chairperson 1999)
 1995 - Present Assistant to ECOG Group Chair for Special Population
 2001 - Present Member, GI Committee NSABP
 2006 - Present Member, Medical Advisory Board, International Myeloma Foundation
 2006 - Present Member, Medical Review Network, Colorectal Cancer Coalition
 2011 - Present Member, Medical Advisory Board, Debbie’s Dream Foundation
 2012 - Present Member, Board of Trustees, National Medical Association
 2012 Member, Test Materials Development Committee, American Society of Clinical Oncology
 2015 - 2016 President, National Medical Association
 2016 - Present Past President, National Medical Association
 2020 - Board President, National Patient Advocate Foundation

University Committees:

Admissions Committee
 Residency Selection Committee
 Human Subjects Review Committee
 Dean’s Search Committee
 Veterans Administration Hospital Research Committee
 Minority Affairs Committee (Chairperson)
 Director of Honors College Search Committee
 Faculty Affairs Committee (current)
 Student Promotions Committee (current)
 Pharmacy and Therapeutics Committee (current)
 Oncology Therapeutics Committee (Chairperson)
 Women’s Networking Committee (current)
 Diversity and Inclusion Committee (current)

Research:

- 1982 - 1984 Principal Investigator – Northern California Oncology Group
 1983 - 1984 Principal Investigator – National Surgical Adjuvant Breast and Bowel Project
 1984 - 1989 Respiratory Committee – Cancer and Leukemia Group B
 1985 - 1992 Director – Minority High School Summer Research Apprentice Program
 1989 - 1992 Director – University of Missouri Sickle Cell Center
 1990 - 1992 Director – Tumor Marker Laboratory
 1988 - 1992 Principal Investigator – Monoclonal Antibody Diagnostic Imaging Project

Current Grants:

- 6/30/96 – 12/31/50 Pharmacia & Upjohn (M/6475/0038), Irinotecan HC1 and 5-Fluorouracil Plus Leucovorin Alone in Patients with Untreated Metastatic Colorectal Cancer.
 PI – Edith P. Mitchell, MD, Award - \$83,200.00
- 4/1/99 – 12/31/50 Sanofi (LTS 7072/0127), A Compassionate Use Study of Oxaliplatin for Previously Treated Colorectal Cancer Patients.
 PI – Edith P. Mitchell, MD, Award - \$117,800.00
- 1/1/01 – 12/31/50 Sanofi-Synthelabo, A Multicenter, Open-Label, Randomized, Three-Arm Study of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) or Oxaliplatin or a Combination of 5 FU/LV + Oxaliplatin as Second-Line Treatment of Metastatic Colorectal Carcinoma.
 PI – Edith P. Mitchell, MD, Award - \$96,000.00
- 1/1/03 – 12/31/50 Roche (XEL198). A Phase/II Trial of Preoperative Radiation Therapy with Concurrent Capecitabine and CPT-11 Chemotherapy for Patients with Locally Advanced or Recurrent Rectal Cancer.
 PI – Edith P. Mitchell, MD, Award - \$72,000.00
- 4/29/03 – 12/31/50 Pharmacia (CPTAIV-0020-411), A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Bolus 5-FU (Day 1 & 8) and Oral Capecitabine (Day 1-14); with Celecoxib vs. Placebo as First Line Therapy for Patients with Metastatic Colorectal Cancer.
 PI – Edith P. Mitchell, MD, Award - \$40,400.00
- 5/9/03 – 12/31/50 Bristol Myers Squibb, ImClone System Inc., Merck KGaA, (CA225014) A Phase III Randomized Multicenter Study of Cetuximab, Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma.
 PI – Edith P. Mitchell, MD, Award - \$45,823.00
- 5/27/03 – 12/31/50 Bristol Myers Squibb, ImClone System Inc., Merck KGaA, (CA225006) Irinotecan and Cetuximab vs Irinotecan as Second Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma.

PI – Edith P. Mitchell, MD, Award - \$28,000.00

7/28/04 – 12/31/50 Immunex Corp., Amgen, Inc. (20030167-1089), A Phase II Multicenter Single Arm Clinical Trial of Panitumumab Monotherapy In Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy.

PI – Edith P. Mitchell, MD, Award - \$117,615.00

5/1/05 – 5/1/50 SuperGen, Inc (SGI-RUB-048), A Double-Blind, Randomized, Multi-Center, Study of Orathecic (Rubitecan) Capsules Plus Gemcitabine versus Placebo Capsules Plus Gemcitabine (With An Open-Label Single-Arm Pre-Randomization Phase) In Chemo-naive Patients with Non- Resectable Pancreatic Cancer.

PI – Edith P. Mitchell, MD, Award - \$59,720.00

6/7/05 – 12/31/50 Amgen/Immunex Corporation (20040249), A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects with Metastatic Colorectal Cancer.

PI – Edith P. Mitchell, MD, Award - \$106,240.00

2012 – Present ECOG/ACRIN/ Thomas Jefferson

PI – Edith P. Mitchell, MD

2018 - Present NIH/NCI: Translational Research in Cancer, Institutional Cancer Center Core Grant

Role: Associate Director, Disparities

2018 – Present Taiho Oncology Inc. A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

PI – Edith P. Mitchell, MD

2019 – Present NIH/NCI: Sidney Kimmel Cancer Center LAPS Institutional Collaboration

Co PI – Edith P. Mitchell, MD

Expired Grants:

6/12/96 – 3/31/00 Pharmacia & Upjohn (M6475-0033), Irinotecan Hydrochloride (CPT-11): Phase II Trial Using an Every-Other-Week Dosing Schedule in Patients Who Have Been Previously Treated With 5-FU Colorectal Cancer.

PI – Edith P. Mitchell, MD, Award - \$58,468.00

4/2/97 – 4/2/00 Sanofi (EFC-2970) A Multicenter Study Evaluating the Addition of Oxaliplatin to 5-Fluorouracil-Based Chemotherapy in Subjects with Advanced Refractory Colorectal Cancer.

- PI – Edith P. Mitchell, MD, Award - \$68,000.00
- 8/1/97 – 3/31/02 Pharmacia & Upjohn, Combined Modality of Locally Advanced or Recurrent Adenocarcinoma of the Rectum with Radiation, 5FU and CPT11 Followed by Surgery.
PI – Edith P. Mitchell, MD, Award - \$153,200.00
- 6/26/98 – 6/30/04 Rhone-Poulenc Rorer (Aventis) (RP56976-V-TAX 325), Open Label, Randomized, Multicenter Phase II/III Study of Docetaxel in Combination with Cisplatin (CDDP) or Docetaxel in Combination with 5-Fluorouracil (F-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients with Metastatic or Locally Recurrent Colorectal Cancer.
PI – Edith P. Mitchell, MD, Award - \$57,800.00
- 4/4/00 – 3/31/05 National Cancer Institute (U01 CA 86127), Special Populations Network for Cancer Control.
PI – Edith P. Mitchell, MD, Award - \$623,248.00
- 6/1/01 – 5/31/02 Protarga (P01-00-03), Phase II Open Label Study of Taxoprexin (DHA-paclitaxel) Injection by 2-Hour Intravenous in Patients with Cancer of the Pancreas.
PI – Edith P. Mitchell, MD, Award - \$45,823.00
- 11/15/01 – 1/1/03 MGI Pharmaceuticals, Phase III Trial of Iroflufen vs 5-Fluorouracil in Patients with Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma.
PI – Edith P. Mitchell, MD, Award - \$52,315.00
- 9/16/02 – 2/1/03 Roche (ML16323) A Phase II Study of Oral Xeloda in Combination with Intravenous Irinotecan for Patients with Locally Advanced and/or Metastatic Colorectal Cancer.
PI – Edith P. Mitchell, MD, Award - \$24,415.00
- 11/1/02 – 12/31/03 Pharmacia & Upjohn, A Phase II, Single-Arm Trial of CPT-11 (Irinotecan HCL: Camptosar (Injection)/Cisplatin in Patients with Advanced Esophageal Cancer.
PI – Edith P. Mitchell, MD, Award - \$29,875.00
- 5/1/02 – 4/30/03 Frontier Science NIH/NCI (CA 21115-28), Minority Initiative.
PI – Edith P. Mitchell, MD, Award - \$9,756.00
- 6/1/02 – 6/1/03 Luitpold Pharmaceuticals, (P01-00-03), Phase II Open Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients with Metastatic Cancer of the Pancreas.
PI – Edith P. Mitchell, MD, Award - \$23,791.24
- 6/1/02 – 5/31/04 Pharmacia Corp, A Phase II, Randomized, Open-Label, Controlled Dose

- Evaluation, Multi-Center Trial of Thalidomide for the Prevention of Diarrhea Associated with Irintotecan/5-Fluorouracil/Leucovorin Chemotherapy in Patients with Previously Untreated Metastatic Colorectal Carcinoma.
PI – Edith P. Mitchell, MD, Award - \$62,153.00
- 8/1/02 – 7/31/03 Daiichi Pharmaceutical, (8951A-PRT0301), A Randomized, Open Label, Multicenter Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951f (Exatecan Mesylate) plus Gemcitabine to Gemcitabine Alone in Patients With Locally Advanced or Metastatic Cancer of the Exocrine Pancreas.
PI – Edith P. Mitchell, MD, Award - \$49,160.00
- 11/2/02 – 12/31/05 Novartis, Pharmaceuticals, PTK 787/ZK 222584 for Colorectal Cancer.
PI – Edith P. Mitchell, MD, Award - \$23,576.00
- 1/1/03 – 12/31/03 Pharmacia (366), Pharmacia CPT AIV 00200 366 Blood Sampling Protocol for Irontecan/Fluorouracil/Leucovorin (CPT-11/FU/LV)
PI – Edith P. Mitchell, MD, Award - \$800.00
- 5/1/03 – 4/30/04 Frontier Science NIH/NCI (CA 21115-29), Minority Initiative.
PI – Edith P. Mitchell, MD, Award - \$10,049.00
- 5/30/03 – 5/1/04 Lorus Therapeutics, A Phase III, Double-Blind, Multicenter, Randomized Study in Chemonaive Patients with Locally Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy of Virulizin plus Gemcitabine versus Placebo plus Gemcitabine: Optional Second-Line Therapy may Include Continuation of Virulizin or Placebo or in Combination with 5-Fluorouracil.
PI – Edith P. Mitchell, MD, Award - \$20,470.00
- 2/1/04 – 8/31/05 Bristol Myers Squibb, (CA225041), Anti-Epidermal Growth Factor (EGFR) Antibody, Cetuximab (C225) in Patients with Stage IV Colorectal Carcinoma Who Failed All Standard Therapy: An Access Protocol
PI – Edith P. Mitchell, MD, Award - \$15,000.00
- 4/1/04 – 3/31/05 National Cancer Institute (U01 CA86127), Breast Cancer Prevention Tool for African American Women.
PI – Edith P. Mitchell, MD, Award - \$31,847.00
- 5/10/04 – 10/24/05 Enzon, Inc., (CAM-9011), An Evaluation of the Efficacy and Safety of PEG-Camptothecin for Second Line Therapy of Locally Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
PI – Edith P. Mitchell, MD, Award - \$14,112.00
- 10/29/04 – 12/15/05 Taiho Pharma (TPU-S1101), A Phase I/II Open Label Nonrandomized,

- Dose Finding Safety, Tolerance, Pharmacogenetic and Efficacy Study of Orally Administered S-1 Combination with Cisplatin in Patients with Advanced Gastric Cancer.
PI – Edith P. Mitchell, MD, Award - \$131,310.00
- 11/4/04 – 5/1/06 Amgen, Inc., (200300250-1090) A Phase II Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFR Levels by Immunohistochemistry Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaplatin.
PI – Edith P. Mitchell, MD, Award - \$106,240.00
- 2/14/05 – 6/1/06 Immunicon Corp (IMMC06), Longitudinal Enumeration of Circulating Tumor Cells in Patients with Metastatic Colorectal Carcinomas.
PI – Edith P. Mitchell, MD, Award - \$3,040.00
- 9/8/05 – 9/7/06 Taiho Pharma U.S.A (TPU-S1301), An Open-Label, Multicenter, Randomized, Phase III Study of S-1 in Combination with Cisplatin Compared Against 5-FU in Combination with Cisplatin in Patients with Advanced Gastric Cancer Previously Untreated with Chemotherapy for Advanced Patients
PI – Edith P. Mitchell, MD, Award - \$79,720.00
- 1/1/03 – 9/30/06 Novartis Pharmaceuticals (CPTK7870135/306241), A Randomized, Double-Blind, Placebo-Controlled Phase III Study in Patients with Metastatic Adenocarcinoma of the Colon or Rectum who are Receiving First Line Chemotherapy with Oxaliplatin/5-Fluorouracil/Leucovorin and PTK 787/ZK 222584 or Placebo.
PI – Edith P. Mitchell, MD, Award - \$42,790.00
- 9/1/03 – 8/31/07 Genentech (TRC-0301), Anti VEGF Monoclonal Antibody Bevacizumab (Avastin) + 5FU/LV in Patients with Metastatic Colorectal Cancer that have Progressed after Standard Chemotherapy
PI – Edith P. Mitchell, MD, Award - \$5,000.00
- 4/20/04 – 8/31/07 Genentech (TRC-0301), A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) Plus 5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancers That Have Progressed after Standard Chemotherapy.
PI – Edith P. Mitchell, MD, Award - \$4,000.00
- 2008 - 2009 Susan G. Komen Foundation, Tumor Markers in Breast Cancer
PI – Terry Hyslop and Edith P. Mitchell, MD, Award - \$35,000.00
- 2008 - 2009 Pennsylvania Department of Health, Healthy Women's Project
PI – Edith P. Mitchell, MD, Award - \$125,000.00
- 7/08 – 7/09 Sanofi Aventis, Study of colon cancer in African-Americans.

PI – Edith P. Mitchell, MD, Award - \$100,000.00

3/10/08 – 3/09/11 Amgen, Inc. (20040205), An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG706 Plus Panitumumab Plus Chemotherapy in Treatment of Metastatic Colorectal Cancer.

PI – Edith P. Mitchell, MD, Award - \$327,390.00

4/7/09 – 4/7/14 Susan G. Komen Foundation: Therapy-relevant Stratification of Breast Cancer Patients: Integrating Pathology and Biomarker Analyses Clinical
Co-PI – Edith P. Mitchell, MD, Award - \$6.7 million

PUBLICATIONS

Journals:

1. Fuks JZ, Van Echo DA, Aisner J, Mitchell EP, Woolley PV III and Wiernik PH. A phase II trial of methyl G. (Methylglyoxal-Bis-Guanylhydrazone) in patients with metastatic cell carcinoma. Cancer Clinical Trials, 4:411-414, 1981.
2. Mitchell EP, Killen JY, Smith EP, Willis LL, Schein PS and Woolley PV III. A phase II study of 1-(2-Chlorethyl)3 (2,6-Dioxo-1-Piperidy 1) 1-Nitosourea in colorectal carcinoma. Cancer Treatment Reports 65: 1129-1130, 1981.
3. Mitchell EP, Schein PS. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 9:52-64, 1982.
4. Killen JY, Mitchell EP, Willis LL, Gullo JJ, Smith FP, Schein PS and Woolley PV. Phase II studies of Methylglyoxal-Bis-Guanylhydrazone(NSC 32946) in carcinoma of the colon and lung. Cancer 50:1258-1261, 1982.
5. Reynolds RD, Sonoda T, O'Dell S, Niemtzow R, Mitchell EP, San Diego A, Anson N, Takamoto R and Greenberg BR. The value of laparotomy in the staging of Hodgkin's disease. Missouri Medicine, 1982.
6. Bonnem EM, Mitchell EP, Woolley PV, Smith FP, Neefe J, Smith L and Schein PS. Phase II trial of mitoxantrone in advanced colorectal cancer. Cancer Treatment Reports 66:1995-1996, 1982.
7. Torti FM, Prozig KJ, Gandara DR, Volberding P, Mitchell EP, Meyers FJ, Kohler M, Gribble M. A phase II trial of 4'-epi-doxurubicin in metastatic melanoma. Cancer Treatment Reports 68:1122-1124, 1984.
8. Meyers FJ, Lewis B, Mitchell EP, William L, Hannigan JF Jr., Gribble M, Torti FM: A phase II trial of 4'-epi-doxurubicin in advanced colorectal carcinoma: An NCOG Study. Cancer Treatment Reports 69:143-145, 1985.
9. Reynolds RD, Greenberg BR, Khojasteh A, Sanda VR, Narayanaswamy T, Lucas RN, Haferman DR, Mitchell EP, Anson NO: An analysis of the histologic evaluation of lung cancer. Missouri Medicine, 82:260-263, 1985.

10. Mitchell EP and Schein PS. Contributions of nitrosoureas to cancer treatment. Cancer Treatment Reports. 70:31-43, 1986.
11. Torti FM, Bristow MM, Carter SK, Mitchell EP, et al. Comparative cardiotoxicity of epirubicin and doxorubicin. Assessment by Endomyocardial Biopsy. Cancer Research 46:3722-3727, 1986.
12. Myers FJ, Cardiff RD, Quadro R, Gribble M, Kohler M, Medrano V, Mitchell EP, Shuffman R, and William L. Epirubicin in non-oat cell lung cancer – response rates and the importance of immunopathology: a Northern Oncology Group Study. Cancer Treatment Reports 70:805-6, 1986.
13. Reynolds RD, McEntire JE, Rodes ND, Dunn PA, Doyle MK, Mitchell EP, Papermaster BW. Phase I clinical trial of an MAI-containing lymphoblastoid cell line supernatant. J Biol Response Modifiers 5:129-139, 1986.
14. Winkler A, Jackson R, Kay DS, Mitchell E, Carmignani S, Sharp G. High-dose intravenous cyclophosphamide treatment of systemic lupus erthematosus-associated aplastic anemia. Arthritis and Rheumatism, 31(5):693-694, 1988.
15. Mitchell EP. Carcinoma of the anal region. Semin Oncol 15:146-153, 1988.
16. Mitchell EP, Schlom J. Monoclonal Antibodies in Gastrointestinal Cancer. Semin Oncol 15:170-180, 1988.
17. Mitchell EP, Rodriguez LV. Perspectives on cancer research in minorities. Head and neck, lung, gastrointestinal, and pediatric cancers. The Cancer Bulletin 40:86-91, 1988.
18. Mitchell EP, Kuo K, Evans L, Schultz P, Madsen R, Gehrke C, Yarbrow J. High performance liquid chromatography of modified nucleosides in human serum. Journal of Chromatography (Bio Medical Application) 581:31-40, 1992.
19. Doerr RJ, Abdel-Nabi H, Krag D, Mitchell EP. Radiolabeled Antibody Imaging In The Management of Colorectal Cancer: Results of a Multicenter Clinical Study. Annals of Surgery 214:118-24; Aug. 1991.
20. Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell EP, Purnell G, Tyson I, Abdel-Nabi H, Winzelberg G. Immunoscintigraphy of Prostate Cancer: Preliminary Results With In-Labeled Monoclonal Antibody 7E11-C5.3(CYT-356) Prostate 18:229-241, 1991.
21. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mitchell E, Purnell G, and Harwood SJ. Monoclonal Antibodies and Radioimmuno Conjugates in the Diagnosis and Treatment of Prostate Cancer. Sem Urology 10:45-54, 1992.
22. Collier BD, Abdel-Nabi H, Doerr RF, Harwood SJ, Olsen J, Kaplan EH, Winzelberg G, Grossman S, Mitchell E. Immunoscintigraphy with In-Cyt-103 in the Management of Colorectal Carcinoma: A comparison with computed Tomography. Radiology 185:179-86, 1992.

23. Mitchell EP, Gastrointestinal Toxicity of Chemotherapeutic Agents. Seminars in Oncology 19:566-579, 1992.
24. Luikart SD, Goutsou M, Mitchell E, Van Echo DA, Modeans CR, Propert KJ, O'Donnell J, Difino S, Perry MC, Green MR. Phase I/II Trial of Etoposide and Carboplatin in Extensive Small Cell Lung Cancer. Am. J. Clin Oncology 16(2) 127-31, 1993.
25. Corman ML, Galandiuk S, Block GE, Prager ED, Weiner GJ, Kahn D, Abdel-Nabi H, Mitchell EP, Pascucci VL, Maroli AN, Maguire RT. Immunoscintigraphy with in-Satumomab Pentitide in Patients with Colorectal Adenocarcinoma: Performance and Impact on Clinical Management. Submitted for Publication. Diseases of the Colon & Rectum. 37(2), 129-37, 1994.
26. Sphall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch Wm, Capizzi RL, Mitchell E, Schein PS, Jones RB. Amifostine (WR-2721) Shortens the Engraftment Period of 4-Hydroxycyclophosphamide Purged Bone Marrow Support. Blood 83:3132-3137, 1994.
27. Capizzi RL, Scheffler B, Reynolds R, Mitchell E, Oster W, Schein PS. Hematologic Cytoprotection by Amifostine (WR-2721). 25th Congress of the International Society of Hematology, Cancun, Mexico. No. 64, 200, 1994.
28. Mitchell EP, Perry MC, Luikart SD, Cirrincione CT, Van Echo DA, Herndon II JE, Maurer H, Clamon G, Green MR. A Phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: A Cancer and Leukemia Group B. Study. Lung Cancer 15: 215-223, 1996.
29. Mitchell EP. Developments in advanced colorectal cancer: New treatment approaches for metastatic disease. Meniscus Publications 1997.
30. Mitchell EP, Advances in the Treatment of Metastatic Colorectal Cancer. Ann Intern Surgery 85:102-108, 1998.
31. Wadler S, Benson AB, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell EP, Rubin J, Trotta P, Vokes E. Recommended Guidelines for the Treatment of Chemotherapy-Induced Diarrhea. Journal of Clinical Oncology, September, 3169-3178, 1998.
32. Mitchell EP, Role of Carcinoembryonic Antigen in the Management of Advanced Colorectal Cancer. Seminars in Oncology. 1999.
33. Mitchell EP. Management of Cancer Treatment-Related Diarrhea: Issues and Therapeutic Strategies. Journal of Pain Symptoms Management, 1999.
34. Mitchell EP, Advances in the Treatment of Metastatic Colorectal Cancer. Surgical Technology International, 1999.
35. Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassell A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ, Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the *c-raf-1* Antisense Oligonucleotide ISIS 5132 (CGP 69846A), Journal of Clinical Oncology, July, 17 (7): 2227-36, 1999.

36. Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D. Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. *Ann NY Acad Sci.* Jun, 910:237-52; discussion 252-3, 2000.
37. Mitchell EP, Irinotecan in Preoperative combined Modality Therapy for Locally Advanced Rectal Cancer. *Oncology* 14: No 12 (Supplement No. 14) 56-59, 2000.
38. Mitchell EP, Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer, *Oncology*, December, 14 (12 Supplement 11), 2000.
39. Anne PR, Edmonston TB, Rose D, Burkholder S, Mitchell E, Kovatich A, Palazzo J, Boman B, Fry R, Curran WJ, Fishel R. Microsatellite instability predicts for tumor response in a prospective trial of preoperative 5-FU, CPT-11 and radiation for locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys*, 48(3S): 121, 22a, 2000.
40. Fava T, Desnoyers R, Schulz S, Park J, Weinberg D, Mitchell E, and Waldman SA: Ectopic Expression of Guanyl Cyclase C in CD34⁺ Progenitor Cells in Peripheral Blood. *Journal of Clinical Oncology*, 19 (18): 3951-3959, 2001.
41. Birebent B, Somasundaram R, Purev E, Weiping L, Mitchell E, Hoey D, Bloom E, Mastrangelo M, Maguire H, Harris DT, Staits L, Braumuller H, Leeser C, Krittner N, Beger H, and Herlyn D. Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. *Clinical Reviews in Oncology/Hematology* 39: 107-113, 2001.
42. Mitchell EP, Anne PR, Fry R, Ahmad N, Boman B, Edmunston T, Rakinic J, Goldstein S, Rose L, Palazzo J, Cagir B, Kovatich A, Hauck W, Fishel R, Bonanni R, Hoey D, Rose D, Curran W. Combined Morality Therapy of Locally Advanced or Recurrent Adenocarcinoma of the Rectum: Report of a Phase I Trial of Chemotherapy (CT) with CPT-11, 5-FU and Concomitant Irradiation (RT). *Proceedings of the American Society of Clinical Oncology*, 519a, 2001.
43. Fava T, Desnoyers R, Schulz S, Park J, Weinberg D, Mitchell E, Waldman SA. Ectopic Expression of Guanyl Cyclase C in CD 34+ Progenitor Cells in Peripheral Blood. *J. Clin Oncol*, October 2001; 19 (19): 3951-3959.
44. Birebent B, Koido T, Mitchell E, Li W, Somasuddaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai E, Herlyn D. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and /or cellular immune responses in animals and colorectal cancer patients. *J. Cancer Res Clin Oncol*, 2001 Oct: 127 Suppl 2:R27-33.
45. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mithcell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee, *Int J Radiat Oncol Biol Phys*, 51 (3 Suppl 2): 19-27, 2001.

46. Herlyn D, Birebent B, Akis N, Purev E, Somasundaram R, Mitchell E, Maguire H, Staib L, Mastrangelo M. Colon Cancer Antigen and Anti-Idiotypic Vaccines. Health Sciences. Oxford, England, 2002.
47. Stein D, Mahmoud N, Rose D, Anne P, Goldstein S, Isenberg G, Mitchell E, Fry R. A Longer Time Interval Between Completion of Neoadjuvant Chemoradiation and Surgical Resection does not Improve Downstaging of Rectal Carcinoma, Diseases of the Colon and Rectum, 45(4):A4-A5, 2002.
48. Benson AB, Mitchell E, Abramson N, Klencke B, Ritch P, Burnhan JP, McGuirt C, Bonny T, Levin J, Hohneker J. Oral Eniluracil/5-Fluorouracil In Patients With Inoperable Hepatocellular Carcinoma, Ann Oncol, Apr; 13(4): 576-581, 2002.
49. Dold F, Hoey D, Freiberg V, Mitchell EP. Hypersensitivities in Patients Treated with Oxaliplatin Chemotherapy. Proceedings of the American Society of Clinical Oncology. 2002.
50. Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nai S, Cai D, Zhang T, Herlyn D. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 2003 Apr 2; 21 (15): 1601-1612.
51. Stein DE, Mahmoud NN, Rose DG, Anne PR, Goldstein SD, Isenberg GA, Mitchell EP, Fry RD. Longer Time Interval Between Completion of Neoadjuvant Chemoradiation and Surgical Resection does not Improve Downstaging of Rectal Carcinoma. Diseases of the Colon and Rectum 46(4): 448-452, April 2003.
52. Ramanathan R, Clark J, Kemeny N, Lenz H-J, Gococo K, Haller D, Mitchell E, Kardinal C. Safety and Toxicity Analysis of Oxaliplatin Combined With Fluorouracil or as a Single Agent in Patients With Previously Treated Advanced Colorectal Cancer. Journal of Clinical Oncology, 21 (15): 2904-2911, 2003.
53. Mitchell E. Prognosis After Rectal Cancer Treatment in Blacks and Whites: Advanced Stage at Diagnosis or Other Factors? Journal of Clinical Oncology, 21 (3): 397-8, 2003.
54. Mitchell E. Challenges of Multiple Myeloma and its Treatments. Myeloma Today, May 2003.
55. Dold FG, Mitchell EP. Sudden-Onset Thrombocytopenia with Oxaliplatin. Annals of Internal Medicine 139 (2): E-156-157, 2003.
56. Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular Surface, Ocular Adnexal, and Lacrimal Complications Associated With the Use of Systemic 5-Fluorouracil. Ophthalmic Plastic and Reconstructive Surgery 19 (3): 216-224, 2003.
57. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea, Journal of Clinical Oncology, July, 2918-2926, 2004.
58. Halbert CH, Kessler LJ, Mitchell EP. Genetic Testing for Inherited Cancer Risks in African Americans. Cancer Investigations, 23(4):285-295, 2005.

59. VanCutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral Capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized phase III trials. British Journal Cancer, March 22, 90(6):1190-1197, 2004.
60. Mitchell, EP. Prognostic Impact of Race and Ethnicity in the Treatment of Colorectal Cancer. Med Clin N Am, Sept 89(5):1045-1057, 2005.
61. Goldstein, MJ, Mitchell, EP. Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer. Cancer Investigations, 23: 338-351, 2005.
62. Mitchell, EP. Gastrointestinal Toxicity of Chemotherapeutic Agents. Semin Oncol, 33(1): 106-120, 2006.
63. Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willet C. Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 00112. Journal of Clinical Oncology, February, 650-655, 2006.
64. Fuchs CS, Mitchell EP, Hoff PM. Irinotecan in the Treatment of Colorectal Cancer. Cancer Treatment Reviews, Nov 32(7): 491-503, 2006.
65. Intenzo CM, Jabbour S, Lin HC, Milder JL, Kim SM, Capuzzi DM, Mitchell EP. Scintigraphic Imaging of Neuroendocrine Tumors. Accepted Journal Nuclear Medicine, 2006.
66. Fuchs CS, Hoff P, Mitchell EP. Irinotecan: Changing the Treatment of Metastatic Colorectal Cancer. Submitted Journal of Clinical Oncology, 2006.
67. Mitchell EP. Advances in Systemic Chemotherapy of Gastric Cancer. Accepted Oncology, 2006.
68. Mitchell EP. Combating Resistance to Chemotherapy: The Cetuximab Experience. Submitted Journal of Clinical Oncology, 2006.
69. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine Phosphorylase Expression is Associated with Response to Capecitabine Plus Irinotecan in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, Sep 1 24(25):4069-4077, 2006.
70. Mohiuddin, M, Winter, K, Mitchell, E, Hanna, N, Yuen, A, Nichols, C, Shane, Robert, Hayostek, C, Willett, C. Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012. Journal of Clinical Oncology, Feb 1 2006: 650-655.
71. Morris GJ, Mitchell EP. Bisphosphonate Therapy for Women with Breast Cancer and at High Risk for Osteoporosis. Journal of the National Medical Association, Jan 99(1): 35- 45, 2007.

72. Mitchell EP. Summary and Future Directions for Investigations in Colon and Gastroesophageal Cancers. John Hopkins Advanced Studies in Medicine, 7 (2): 50 – 54, 2007.
73. Marsh RW, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM, Benson AB. A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology, Feb 30(1): 26 – 31, 2007.
74. Morris G, Naidu S, Topham A, Guiles F, Chervoneva I, McCue P, Schwartz G, Park P, Rosenberg A, Sabol J, Brill K, Mitchell E. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients; a single-institution compilation compared with the National Cancer Institute SEER database. Cancer, 110 (4): 876-884, 2007.
75. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, III. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 25 (12): 1539-1544, 2007.
76. Mitchell EP, Perez-Solar R, VanCutsem E, Lacouture ME. Clinical Presentation and Pathophysiology of EGFR Dermatologic Toxicities. Oncology, 21 (11) Supplement 5: 4 – 9, 2007.
77. Lacouture ME, Cotliar J, Mitchell EP. Clinical Management of EGFR Dermatologic Toxicities: US Perspective. Oncology, 21 (11) Supplement 5: 17 – 21, 2007.
78. Fuchs CS, Marshall J, Mitchell EP, Wierzbicki R, Ganju V, Jeffery M, Schultz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results from the BICC-C Study. Journal of Clinical Oncology, 25 (30): 4779 – 4786, 2007.
79. Intenzo CM, Jabbour S, Lin HC, Miller JL, Kim SM, Capuzzi DM, Mitchell EP. Scintigraphic Imaging of Body Neuroendocrine Tumors. RadioGraphics, 27 (5): 1355 – 1369, 2007.
80. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosa I, Radinsky R, Amado RG. Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone. Clinical Colorectal Cancer, 7 (3): 184 - 190, 2008.
81. Morris GJ, Mitchell EP. Higher Incidence of Aggressive Breast Cancers in African-American Women: A Review. Journal of the National Medical Association, 100 (6): 698 – 702, 2008.
82. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Meropol NJ. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26 (19): 3213 – 3221, 2008.
83. Langerak A, River G, Mitchell E, Puneet C, Shing M. Panitumumab Monotherapy in Patients with Metastatic Colorectal Cancer and Cetuximab Infusion Reactions: A Series of Four Case Reports. Clinical Colorectal Cancer, 8 (1): 49 – 54, 2009.

84. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hangenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared with Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 27 (5): 672 – 680, 2009.
85. Lacouture ME, Mitchell EP, Piperdi B, Madhavan PV, Shearer H, Iannotti N, Xu F, Yassine M. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 28 (8): 1351 – 1357, 2010.
86. Kreuger C, Mitchell E. Management of Epidermal Growth Factor Receptor Inhibitor-Induced Dermatology Toxicity. Clinical Oncology News, 5 (4) Supplement: 1-8, 2010.
87. Witkiewicz, A. K, Dasgupta, A., Sammons, S., Er, O., Potoczek, M. B., Guiles, F., Sotgia F., Brody, J. R., Mitchell, E. P., and Lisanti, M. P. Loss of Stromal Caveolin-1 Expression Predicts Poor Clinical Outcome in Triple Negative and Basal-Like Breast Cancers. Cancer Biology & Therapy, 10 (2): 1-9, July 15, 2010.
88. Showalter SL, Rosato EL, Anne PR, Scott W, Mitchell E, Berger AC. Does diabetes mellitus influence pathologic complete response and tumor downstaging after neoadjuvant chemoradiation for esophageal and gastroesophageal cancer? A two-institution report. Journal of Surgical Oncology, 101(1):43-6, 2010 Jan 1.
89. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clinical Cancer Research, 16(7): 2205-2213, 2010 Apr 1.
90. Noto KA, Almario C, Maxwell PJ, Mitchell EP, Isenberg GA, Goldstein SD. Long-term survival after colonic stenting and restenting for malignant colonic obstruction. American Journal of Surgery, 76(4): 457-459, 2010 Apr.
91. Gonsalves CF, Mitchell EP, Brown DB. Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer. American Journal of Roentgenology, 195(5):1241-1244, 2010 Nov.
92. Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, Berger AC. Do Elderly Patients Experience Increased Perioperative or Postoperative Morbidity or Mortality When Given Neoadjuvant Chemoradiation Before Esophagectomy? International Journal of Radiation Oncology, Biology, Physics, 80(5):1372-1376, 2011 Aug 1.
93. Showalter TN, Zhan T, Anne PR, Chervoneva I, Mitchell EP, Yeo CJ, Rosato EL, Kennedy EP, Berger AC. The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma. Journal of Gastrointestinal Surgery, 15(8):1411-1416, 2011 Aug.

94. Gray NM, Hall SJ, Browne S, Macleod U, Mitchell E, Lee AJ, Johnston M, Wyke S, Samuel L, Weller D, Campbell NC. Modifiable and fixed factors predicting quality of life in people with colorectal cancer. British Journal of Cancer, 104(11):1697-1703, 2011 May 24.
95. Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, Xu F, Yassine M. The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by *KRAS* Status. Clinical Colorectal Cancer, 10(4):333-339, 2011 December.
96. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLoS One, 7(1): e29797; 2012 Jan 17.
97. Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Radiation Therapy Oncology Group 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin with Concurrent Radiotherapy for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics, 82(4):1367-75. 2012 Mar 15.
98. Hurwitz H, Mitchell EP, Cartwright T, Kwok A, Hu S, McKenna E, Patt, YZ. A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). Oncologist, 17 (7):937-946, July 2012.
99. Yoder MC, Bannon JP, Mitchell EP, Morris GJ. Mucinous colloid carcinoma of the colon metastatic to the breast. Semin Oncol, 39(3):e1-7, June 2012.
100. Mitchell, Edith P. Colorectal Cancer in the Young. Colorectal Cancer, 1 (5): 355-358, 2012.
101. Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clinical Colorectal Cancer, 12(2):73-85. June 2013.
102. Aggarwal, C, Meropol NJ, Punt, CJ, Iannotti, N, Saidman, BH, Sabbath KD, Gabrail, NY, Pincus, J, Morose, MA, Mitchell E, Miller MC, Cohen, SJ. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Annals of Oncology, 24 (2): 420-428, February 2013.
103. Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BYS, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP. A randomized, placebo-controlled phase 2 study of Ganitumab or Conatumumab in combination with FOLFIRI for second-line treatment of mutant *KRAS* metastatic colorectal cancer. Annals of Oncology, 24 (7): 1777-1785, July 2013.
104. Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols R, Yalavarthi S, Hayostek C, Willett C. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2

- study of neoadjuvant combined modality chemoradiation for distal rectal cancer. International Journal of Radiation Oncology, Biology, Physics, 86(3):523-528, July 2013.
105. Paudyal B, Zhang K, Chen C, Wampole ME, Mehta, N, Mitchell EP, Gray, BD, Mattis JA, Pak, KY, Thakur, ML, Wickstrom E. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nuclear Medicine and Biology, 40(8): 994-999, November 2013.
 106. Wampole ME, Kairys JC, Mitchell EP, Ankeny ML, Thakur ML, Wickstrom E. Consistent surgeon evaluations of three-dimensional rendering of PET/CT scans of the abdomen of a patient with a ductal pancreatic mass. PLoS One, 8(9):e75237, 2013.
 107. Zhao F, Chang VT, Cleeland C, Cleary JF, Mitchell EP, Wagner LI, Fisch MJ. Determinants of Pain Severity Changes in Ambulatory Patients With Cancer: An Analysis From Eastern Cooperative Oncology Group Trial E2Z02. J Clin Oncol, 32(4): 312-319, February 2014.
 108. Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol, 2014 Mar 28. [Epub ahead of print]
 109. Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt N, Mitchell EP, Davidenko I, Stephenson J, Elez ME, Prenen H, Deng H, Tang R, McCaffery I, Oliner K, Chen L, Gansert JL, Loh E, Smethurst D, Tabernero J. Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab With Panitumumab versus Panitumumab Alone in Patients With Wild-Type KRAS Metastatic Colorectal Cancer. Clin Cancer Res, 2014 Aug 15; 20(16):4240-50.
 110. Chen Y, Bekhash A, Kovatich AJ, Hooke JA, Liu J, Kvecher L, Fantacone-Campbell JL, Mitchell EP, Rui H, Mural RJ, Shriver CD, Hu H. Positive Association of Fibroadenomatoid Change with HER2-Negative Invasive Breast Cancer: A Co-Occurrence Study. PLoS One [3.234]. 2015; 10(6):e0129500.
 111. Davey MP, Bilkins B, Diamond G, Willis AI, Mitchell EP, Young FM. African American Patients' Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment. J Cancer Educ, 2015 June 7. [Epub ahead of print]
 112. Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Maneval EC, Paolini J, Lechuga MJ, Kretzschmar A. Five-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) plus Sunitinib or Bevacizumab as First-line Treatment for Metastatic Colorectal Cancer: A Randomized Phase IIb Study. Cancer Management and Research, 7: 165-173, 2015.
 113. Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 2015 Jan 1; 91(1):116-23.
 114. Kleinberg LR, Catalano PJ, Forastiere AA, Keller SM, Mitchell EP, Anne PR, et al. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network randomized phase 2 trial of neoadjuvant preoperative paclitaxel/Cisplatin/Radiation therapy (RT) or

- Irinotecan/Cisplatin/RT in esophageal adenocarcinoma: Long-term outcome and implications for trial design. International Journal of Radiation Oncology Biology Physics, 2016; 94(4), 738-746.
115. Ashing KT, Lai L, Brown S, McDowell K, Carter D, Smith J, Mitchell E, Santifer RH, Martin V, Betts-Turner B, Fielder O, Miller V. Developing a treatment summary and survivorship care plan responsive to African-American breast cancer survivors. Psycho-Oncology 2016 Jun; 25(6):729-31.
 116. Goodman CR, Sato T, Peck AR, Gironde MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene, 2015 Jun 22. [Epub ahead of print]
 117. Mitchell EP. The National Medical Association: True North Toward Health Care Equity. J Natl Med Assoc, 2016 Feb; 108(1):1-3.
 118. Mitchell E. Moonshot Toward a Cure for Cancer. J Natl Med Assoc, 2016 May; 108(2):104-5.
 119. Ashing KT, Lai L, Brown S, McDowell K, Carter D, Smith J, Mitchell E, Santifer RH, Martin V, Betts-Turner B, Fielder O, Miller V. Developing a treatment summary and survivorship care plan responsive to African-American breast cancer survivors. Psychooncology, 2016 Jun; 25(6):729-31.
 120. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol, 2016 Jun; 11(3):383-400.
 121. Peck AR, Gironde MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Mod Pathol, 2016 Jun 17. [Epub ahead of print]
 122. Garg MK, Zhao F, Lee J, Sparano J, Palefsky J, Henry D, Wachsman W, Rajdev L, Abouafia D, Mitchell E, Onitilo A, El-Rayes B, Nabbout N, Fitzgerald T, Mitsuyasu R, Benson AB, Kachnic LA. Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045). Int J Radiat Oncol Biol Phys, 2016 Oct 1; 96(2S):S106-S107.
 123. Bernard B, Muralidhar V, Chen YH, Sridhar, SS, Mithcell, EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of Ethnicity on the Outcome of Men with Metastatic, Hormone-Sensitive Prostate Cancer. Cancer, 2017 May 01; 123(9):1536-1544.
 124. Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB 3rd. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anan Carcinoma: A Phase II

- Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol, 2017 Mar; 35(7):718-726.
125. Bleiberg H, Decoster G, deGramont A, Rougier P, Sobreo A, Beson A, Chibaudel B, Douillard JY, Eng C, Fuchs C, Fujii M, Labianca R, Larsen AK, Mitchell E, Schmoll HJ, Sprumont D, Zalberg, J. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. Annals of Oncology, 2017 May; 28 (5): 922-930.
 126. Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, Hayes DF. American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. J Clin Oncol, 30 2017 Apr; 35(22):2576-2579.
 127. Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A. How Health-Related Quality of Life Assessment Should be Used in Advanced Colorectal Cancer Clinical Trials. Ann Oncol, 2017 Sep 01; 28(9):2077-2085.
 128. Frazer E, Mitchell RA, Nesbitt, LS, Williams M, Mitchell EP, Williams RA, Browne D. The Violence Epidemic in the African American Community: A Call by the National Medical Association for Comprehensive Reform. Journal of the National Medical Association, 2018 Feb; 110(1): 4-15.
 129. Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients with Metastatic Colorectal Cancer: A systematic Review. Clinical Colorectal Cancer, 2018 June; 17(2):85-96.
 130. Caplan AL, Teagarden JR, Kearns L, Bateman-House AS, Mitchell E, Arawi T, Upshur R, Singh I, Rozynska J, Cwik V, Gardner SL. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials. J Med Ethics, 2018 Nov; 44(11):761-767.
 131. Tran TH, Utama FE, Sato T, Peck AR, Langenhejm JF, Udhane SS, Sun Y, Liu C, Gironde MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. Clinical Cancer Research, 2018 Dec 15; 24(24):6355-6366.
 132. Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Bergom C, Joshi A, Auer P, Prokop J, Rui H, Flister MJ. Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. Breast Cancer Research and Treatment, 2019 Aug; 177(1):77-91.
 133. Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci F, Mancao C, Lenz HJ. MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clinical Cancer Research, 2019 May; 25(10):2988-2995.

134. Sadigh G, Gallagher K, Obenchain J, Benson A, Mitchell E, Segngupta S, Carlos R. Pilot feasibility study of an oncology financial navigation program in brain cancer patients. Journal of the American College of Radiology, 2019 October; 16(10): 1420-1424.
135. Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. Annals of Oncology, 2019 Nov 1; 30(11):1821-1830.
136. Mitchell EP. Attacking Cancer Death Rates. Journal of the National Medical Association, 2019 Dec; 111(6):577.
137. Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Oncologist, 2019 Dec 18. [Epub ahead of print]
138. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, NCI-MATCH Team. THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN. Journal of the National Cancer Institute, 2020 Jan 10. [Epub ahead of print]
139. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol [44.544]. 2020 01 20; 38(3):214-222. PMID: 31765263 PMCID: PMC6968795 DOI: 10.1200/JCO.19.00818
140. Mitchell EP. 2020 Vision: Continuing Declines in Cancer Incidence and Mortality Rates. Journal of the National Medical Association, 2020 Feb; 112(1):1-2. PMID: 32169164 PII: S0027-9684(20)30021-3 DOI: 10.1016/j.jnma.2020.02.002
141. Mitchell EP. Corona Virus: Global Pandemic Causing World-Wide Shutdown. Journal of the National Medical Association, 2020 Apr; 112(2):113-114. PMID: 32253007 PMCID: PMC7128812 PII: S0027-9684(20)30067-5 DOI: 10.1016/j.jnma.2020.03.015
142. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA,

- Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology, 2020 May 28;JCO1902630. [Epub ahead of print]
143. Mitchell EP. COVID-19 Innovations: Addressing Rapidly Changing Clinical Needs. Journal of the National Medical Association, 2020 Jun; 112(3):237-238. PMID: 32709271 PMCID: PMC7373396 PII: S0027-9684(20)30125-5 DOI: 10.1016/j.jnma.2020.06.004.
144. Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, Fuchs SY. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biology & Therapy, July 2020; 21(7): 629-636.
145. Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research, April 2020; 26(8): 1818-1819.
146. Savitch SL, Grenda TR, Scott W, Cowan SW, Posey J, Mitchell EP, Cohen SJ, Yeo CJ, Evans NR. Racial Disparities in Rates of Surgery for Esophageal Cancer: A Study from the National Cancer Database. Journal of Gastrointestinal Surgery, 2021 03; 25(3):581-592. PMID: 32500418 PII: 10.1007/s11605-020-04653-z DOI: 10.1007/s11605-020-04653-z
147. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty, KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology, July 2020; 38(21): 2407–2417.
148. Mitchell EP. The National Medical Association 1895-2020: Struggle for Healthcare Equity in the United States of America. Journal of the National Medical Association, 2020 Aug; 112(4):331-332. PMID: 32891361 PMCID: PMC7467650 PII: S0027-9684(20)30163-2 DOI: 10.1016/j.jnma.2020.08.001
149. Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Dabrafenib and Trametinib in Patients With Tumors With Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology, 2020 11 20; 38(33):3895-3904. PMID: 32758030 PMCID: PMC7676884 DOI: 10.1200/JCO.20.00762
150. Mitchell EP. Risk Trends in Colorectal Cancer. Journal of the National Medical Association, 2020 Oct; 112(5):445. PMID: 33292929 PII: S0027-9684(20)30356-4 DOI: 10.1016/j.jnma.2020.10.002
151. Mitchell EP. National Medical Association Celebrates the 125th Anniversary: Much Done, But Lots More to Do. Journal of the National Medical Association, 2020 Oct; 112(5S):S1. PMID: 33308710 PII: S0027-9684(20)30378-3 DOI: 10.1016/j.jnma.2020.10.005

152. Au C, Gupta E, Khaing P, Dibello J, Chengsupanimit T, Mitchell EP[CRC], West FM, Baram M, Awsare BK, Kane GC. Clinical presentations and outcomes in pulmonary embolism patients with cancer. Journal of Thrombosis and Thrombolysis. 2021 Feb; 51(2):430-436. PMID: 33047244 PII: 10.1007/s11239-020-02298-y DOI: 10.1007/s11239-020-02298-y
153. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, NCI-MATCH Team. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst[13.506]. 2020 10 01; 112(10):1021-1029. PMID: 31922567 PMCID: PMC7566320 PII: 5699915 DOI: 10.1093/jnci/djz245.
154. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, LaFrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffee B, Fu T, Routbort M, Zwiebel JA, Rubinstein, LF, Little RF, Arteaga CL, Comis R, Abrams, JS, O'Dwyer PJ, Conley BA. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, Nov 2020; 38(33): 3883-3894. PMID: 33048619 PMCID: PMC7676882 DOI: 10.1200/JCO.19.03010
155. Holcombe RF, Verschraegen CF, Chapman AE, Gaffney D, Goldberg RM, Mesa RA, Milhem M, Mims M, Mitchell EP, Mulkerin D, Vijayakumar S. Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care. Journal of the National Comprehensive Cancer Network, 2021 02; 19(2):122-125. PMID: 33545684 PII: jnccn20530 DOI: 10.6004/jnccn.2020.7685
156. Mitchell EP. COVID-19 and the Cancer Patient: What Every Physician Needs to Know. Journal of the National Medical Association, 2021 Feb; 113(1):1-2. PMID: 33583495 PMCID: PMC7878114 PII: S0027-9684(21)00009-2 DOI: 10.1016/j.jnma.2021.01.002
157. Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol[31.777]. 2021 Feb 01; 7(2):271-278. PMID: 33377972 PMCID: PMC7774047 PII: 2774443 DOI: 10.1001/jamaoncol.2020.6741
158. Musselwhite LW, May FP, Salem ME, Mitchell EP. Colorectal Cancer: In the Pursuit of Health Equity. Am Soc Clin Oncol Educ Book[UK]. 2021 Mar; 41:108-117. PMID: 34010044 DOI: 10.1200/EDBK_321071
159. Mitchell EP. Remembering Jane Cooke Wright, M.D., a Black Woman, Who was Among Seven Founders of the American Society of Clinical. Journal of the National Medical Association, 2021 Apr; 113(2):121-123. PMID: 33845944 PII: S0027-9684(21)00045-6 DOI: 10.1016/j.jnma.2021.02.010

160. Mitchell EP. Cancer in African Americans: Screening can make a Difference. Journal of the National Medical Association, 2021 Aug; 113(4):365. PMID: 34412822 PII: S0027-9684(21)00119-X DOI: 10.1016/j.jnma.2021.07.001
161. Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. J Drugs Dermatol. 2021 Sep 01; 20(9):3ss-s19. PMID: 34491030 PII: S1545961621S03ssX DOI: 10.36849/jdd.6229
162. Mitchell EP. U.S. Preventive Services Task Force Final Recommendation Statement, Evidence Summary, and Modeling Studies on Screening for Lung Cancer. Journal of the National Medical Association, 2021 Jun; 113(3):239-240. PMID: 34274036 PII: S0027-9684(21)00083-3 DOI: 10.1016/j.jnma.2021.05.012
163. Cleary JM, Wang VX, Heist RS, Kopetz S, Mithell EP, Zweibel J, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein L, Patton D, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley B, Aguirrer A, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clinical Cancer Research, 2021 Jun 01; 27(11):2996-3004. PMID: 33637626 PII: 1078-0432.CCR-21-0066 DOI: 10.1158/1078-0432.CCR-21-0066
164. Parker BW, McAneny BL, Mitchell EP, Lopez AM, Russo SA, Maxwell P, Ford LG, McCaskill-Stevens W for the National Cancer Institute PARTNRS Planning Committee. Establishing a Primary Care Alliance for Conducting Cancer Prevention Clinical Research at Community Sites. Cancer Prevention Research, Published online October 5, 2021 DOI: 10.1158/1940-6207.CAPR-21-0019
165. Garrick O, Mesa R, Ferris A, Kim ES, Mitchell E, Brawley OW, Carpten J, Carter KD, Coney J, Winn R, Monroe S, Sandoval F, Perez E, Williams M, Grove E, Highsmith Q, Richie N, Begelman SM, Collins AS, Freedman J, Gonzales MS, Wilson G. Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials. Ethnicity & Disease, 2022; 32(1): 61-68. DOI: 10.18865/ed.32.1.61
166. Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II study of copanlisib in patients with tumors with PIK3CA mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol Published online February 8, 2022. DOI: 10.1200/JCO.21.01648; PMID: 35133871.
167. Anuradha A. Shastri AA, Lombardo J, Okere SC, Higgins S, Smith BC, DeAngelis T, Palagani A, Hines K, Monti DA, Volpe S, Mitchell EP, Simone NL. Personalized Nutrition as a Key Contributor to Improving Radiation Response in Breast Cancer. Int. J. Mol. Sci. 2022, 23(1), 175. DOI: 10.3390/ijms23010175.
168. Mitchell EP. Closing Gaps in Cancer Screening: The President's Cancer Panel Report. Journal of the National Medical Association, 2022, 114(1), 1-2. DOI: 10.1016/j.jnma.2022.02.003.

169. Mitchell E, Alese OB, Yates C, Rivers B, Blackstock W, Newman L, Davis M, Byrd G, Harris AE. Cancer healthcare disparities among African Americans in the United States. Journal of the National Medical Association. Published online March 21 2022. DOI: 10.1016/j.jnma.2022.01.004.

Book Chapters:

1. Mitchell EP, Schein PS. Acute and long-term complications of cytotoxic and immunosuppressive chemotherapy in Clinical Approach to Poisons and Drug Overdose, L.M. Haddad and J.F. Winchester, Eds., Philadelphia, WB Saunders, 1983.
2. Mitchell EP, Schein PS. Gastrointestinal Toxicity of chemotherapeutic agents in Toxicity of Chemotherapy, M.C. Perry and J.W. Yarbro, Eds. New York, Grune and Stratton, 1984.
3. Papermaster BW, McEntire JE, Reynolds RD, Mitchell EP, et al. Measurement of macrophage phagocytic activity in patients following administration of a human B-cell lymphoblastoid MAF preparation, in Cellular and Molecular Biology of Lymphokines, New York, Academic Press, pp. 809-814, 1985.
4. Mitchell EP. Management of Nausea and Vomiting, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 86.
5. Mitchell EP. Red Blood Cell Transfusions, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 232.
6. Mitchell EP. Management of Transfusion Reactions, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 86.
7. Mitchell EP. Platelet Transfusions, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 236.
8. Mitchell EP. Granulocyte Transfusions, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 238.
9. Mitchell EP. Apheresis Procedures in the Management of Malignant Diseases, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 240.
10. Mitchell EP. Cancer of the Anal Region, Decision Making in Oncology, Philip S. Schein, editor, C.V. Mosby, Inc., New York. 1989, p. 86.
11. Mitchell EP, Kuo K, Evans L, Schultz P, Madsen R, Gehrke C, Yarbro J. High performance liquid chromatography of nucleosides in human serum in CW Gehrke and dKC Kuo (eds) Chromatographics and other Analytical Methods in Nucleic Acids Modification Research, Vol 1 Elsevier Scientific Publishers, Amsterdam, 1989.
12. Mitchell EP. Solid tumors in Black Americans. In Lovell Jones (ed), Cancers in Minority Populations, Elsevier Scientific Publishers, Philadelphia, 1989.

13. Mitchell EP. Management of pulmonary metastases, in Pulmonary Medicine: A Concise Textbook, Braun S, Sunderrajan EV, editors, Elsevier Science Pub. Co., New York. (In press).
14. Mitchell EP, Schein PS. Complications of Cytotoxic and Immunosuppressive Therapy in Clinical Approach to Poisons and Drug Overdose, LM Haddad and JF Winchester, Eds, Philadelphia, WB Saunders. 1990.
15. Mitchell EP. Gastrointestinal Toxicity of Chemotherapy in The Chemotherapy Source Book, MC Perry (Ed), Baltimore, Williams and Wilkins, 1992, p. 620.
16. Mitchell EP. Nitrosoureas in The Chemotherapy Source Book, MC Perry (Ed), Baltimore, Williams and Wilkins, 1992, p. 384.
17. Mitchell EP. Nausea and Vomiting in Conn's Current Therapy, R. Rakel (Ed.), W.B. Saunders, Philadelphia, 1991, p. 5-9.
18. Mitchell EP, Glicksman AS, Schein PS. Acute and Late Effects of Cancer Therapy and Their Management in Medical Oncology Second Edition, P. Calabresi and P.S. Schein (Eds.), McGraw-Hill, New York, 1993, p. 345-369.
19. Mitchell, EP, Reynolds RD, Graden D, Capizzi RL. Chemotherapy and Radiation Protection with Amifostine: Clinical Studies in Radiation and the Gastrointestinal Tract. A. Dubois, G.L. King and D.R. Livengood (Eds.), CRC Press, Boca Raton, 1995, pp. 215-224.
20. Mitchell EP. Advances in Systemic Chemotherapy of Gastric Cancer in Advances in the Treatment of Gastric Cancer. Macdonald, JS (Ed.), CMPMedica, The Oncology Group, Manhasset, NY, 2006, pp. 55 – 68.

Abstracts:

1. Mitchell EP, Killen J, Willis L, Winokur S, Smith FP, Schein PS and Woolley PV: Phase II studies of 1-(2-Chlorethyl)-3-(2,6-Dioxo-1-Piperdyl)-1-Nitrosourea (PCNU, NSC, 85466) in colorectal carcinoma, melanoma and hypernephroma. Proceedings American Society of Clinical Oncology 22:455, 1981.
2. Mitchell EP, Killen J, Korsmeyer JS, Young K, Gullo J, Alvarez C, Smith FP, Schein P and Woolley P: Phase II studies with methylglyoxal-Bis-Guanylhydrazone (Methyl G). Proceedings of the American Association of Cancer Research 72:166, 1981. (Poster presentation).
3. Mitchell EP, McCabe M, Smith FP, Goldberg D, MacDonald JS, and Schein PS: Delta-9-Tetra-Hydrocannabinol (THC) for nausea and vomiting caused by cancer chemotherapy. Proceedings of the Society of Air Force Physicians 23:48, 1981. (Slide presentation).
4. Mitchell EP, Voith MA and Cadrette JM: T-Cell lymphoblastic lymphoma in adults. Proceedings of the Society of Air Force Physicians 24:28, 1982. (Slide presentation).
5. Voith MA, Mitchell EP and Kolesar, MA: Extramammary Carcinoma Metastatic to the Breast. Proceedings of the Society of Air Force Physicians 24:28, 1982. (Slide presentation).

6. Bonnem E, Mitchell EP, Smith F, Bowers MW, Neefe J, Brereton H, Winokur S, Haidak D, Green P, Schein P and Woolley P: A phase II trial of dihydorxy-anthracedione (DHAD) in advanced colon cancer. Proceedings of the American Society of Clinical Oncology 23:376, 1982.
7. Mitchell EP, Harris M, Smith FP and Neefe JR: Phase I trial of human leukocyte interferon. Proceedings of the American Society of Clinical Oncology 23:54, 1982. (Slide Presentation).
8. Mitchell EP, Rahman A, Guterrez P, Brereton H and Woolley P: The pharmacologic interaction of m-AMSA with other drugs. Proceedings of the American Association of Cancer Research 73:808, 1982. (Slide Presentation).
9. Mitchell EP, Smith KH, Galey WT and Michels R: Carcinoid tumors of the uterine cervix. Society of Air Force Physicians 25:26, 1983. (Slide Presentation).
10. Brietzke S, Roman N, Mitchell EP: Extranodal presentation of nonhodgkin's lymphoma. Society of Air Force Physicians 25:14, 1983.
11. Feehan P, Quinn D and Mitchell EP. Busulfan lung presenting at an uncharacteristically short duration of therapy. Society of Air Force Physicians 25:14, 1983.
12. Brietzke S, Roman NM and Mitchell EP: Elevated lactic dehydrogenase as a principal manifestation of malignancy in 45 year old women. Society of Air Force Physicians 26:10, 1984.
13. Roman NM , Camp R and Mitchell EP: Leptomeningeal carcinomatosis in breast cancer. Society of Air Force Physicians 26:24, 1984.
14. Mitchell EP, Reynolds RD, Meyers FJ, Medrano V, William L, Koretz M, McGrather L and Torti FM: A phase II study of 4-Epi-Doxorubicin in the treatment of advanced non-small cell carcinoma of the lung. Proceedings of the American Society of Clinical Oncology 20:228, 1984. (Poster Presentation).
15. Garcia AR, Khojasteh A, Anson N, Reynolds RD, Doyle MK, Walter J, Highbarger T, Walker P, Mitchell EP, Kerr D, Kapoor N, McEntire J, Jacobs D, LeGrand R, Oxenhandler R, Paden J, Rodes ND and Papermaster BW. Immunoendocrine changes due to lymphoblastoid MAF in phase I clinical trials: a study of nine patients with disseminated cancer. Proceedings American Society of Clinical Oncology 20:67, 1984.
16. Torti FM, Bristow MR, Howes AE, Aston D, Kohler M, Mitchell EP and Billingham ME. Preliminary observation on the cardiotoxicity of 4'-epi-doxorubicin. Proceedings of the American Association for Cancer Research 75:48, 1984.
17. Reynolds RD, McEntire J, Khojasteh A, Mitchell E, et al. The phagocytic index as a measure of macrophage. Activation Factor from the RMP1-1788 lymphoblastoid cell line. Proceedings American Society of Clinical Oncology 1985.
18. Mitchell E, Reynolds R, Khojasteh A, McEntire J, et al. Urinary excretion of interferon, albumin, and B₂ microglobulin during lymphokine treatment. Proceedings American Society of Clinical Oncology 1985.

19. Reynolds R, Khojasteh A, Mitchell E, Anson NO, et al. MOMAS combination chemotherapy in prior treated advanced breast cancer. Proceedings American Society of Clinical Oncology 1985.
20. Ringenberg QS, Yarbrow JW, Doll DC, Mitchell EP. Honors program in medical oncology: A program in clinical research. Innovations in Medical Education, Group on Medical Education. Amer. Assoc. of Medical Colleges, P. 64, 1986.
21. Mitchell EP, Gehrke CW, Yarbrow J, Owns L, McEntire J, and Kuo K. Modified nucleoside levels in the serum of patients with chronic lymphocyte leukemia. Proc. American Assoc. for Cancer Research, 1987.
22. Luikart SD, Mitchell EP, Van Echo DA, Propert K, Modes C, Perry MC, and Green M. Phase I/II Trial of Etoposide (VP-16) and Carboplatin (CBCDA) in untreated extensive small cell lung cancer (SCLC) Proceedings of American Society of Clinical Oncology 7:195, 1988.
23. Mitchell EP, Luikart S, Van Echo DA, Propert K, Modes C, Perry MC, and Green M. Etoposide (VP-16) and cisplatin (DDP) in untreated small cell lung cancer: A dose-escalation study. Proceeding American Society of Clinical Oncology 7-206, 1988.
24. Mitchell EP, Gehrke CW, Kuo K, McEntire J, and Yarbrow JW. Identification and quantification of modified nucleosides in patients with malignant diseases. Proceedings American Society of Clinical Oncology 8:9, 1989.
25. Sylvester G, Singh A, Volkert W, Patterson WP, Holmes RA. Imaging of Human Adenocarcinoma with IN-111 Labeled B72.3 Monoclonal Antibody. American Society of Nuclear Medicine, 1989.
26. Luikart SD, Mitchell EP, Van Echo DA, Modes C, Goutsou M, Propert K, Perry MC, and Green MR for the Cancer and Leukemia Group B. Phase II Trial of High Dose Etoposide (VP16) and Carboplatin (CBDCA) in Extensive Small Cell Lung Cancer. Proceedings American Society of Clinical Oncology, 1990.
27. Mitchell EP, Luikart SD, Van Echo DA, Modes C, Goutsou M, Propert K, Perry MC, and Green MR for the Cancer and Leukemia Group B Etoposide (VP16) and Cisplatin (DDP): Phase I/II Trial in Extensive Small Cell Lung Cancer. American Society of Clinical Oncology, 1990.
28. Mitchell EP, Singh A, Volkert W, Patterson WP, Holmes RA. Imaging of Human Adenocarcinoma with IN-111 Labeled B72.3 Monoclonal Antibody. Monoclonal Antibody Conference 1990.
29. Mitchell EP, Froe FD, Weinstein S, Volkert W, Baker P, Singh A, Yarbrow J, Holmes R. ¹¹¹Indium Labeled Monoclonal Antibody (MoAB): ¹¹¹IN-CYT-356, Imaging in Carcinoma of the Prostate. Proceedings American Society of Clinical Oncology 10:31, 1991.
30. Weiner G, Kahn D, Jochimsen P, Mitchell E, Sardi A, Harmon J, Bass B, and Paterson B. Immunoscintigraphy with ¹¹¹IN-CYT-193 of Patients with Potentially Resectable Recurrent Colorectal Adenocarcinoma. Proceedings American Society of Clinical Oncology 11:200, 1992.

31. Glick J, Kemp G, Rose P, Mitchell E, Reynolds R, Scheffler B, Capizzi R. Randomized Trial of Cyclophosphamide and Cisplatin Plus/Minus Amifostine in the Treatment of Advanced Epithelial Ovarian Cancer. Proceedings American Society of Clinical Oncology 13:1485, 1994.
32. Fox K, Glick J, MacDonald J, Demers L, Conner G, Jones B, Watts P, Reynolds R, Mitchell E, Capizzi R, Schein P. Randomized Phase II Trial of Rogletimide (ROG) for the Treatment of Locally Advanced or Metastatic Breast Cancer: A Preliminary Report. Proceedings American Society of Clinical Oncology 13:164, 1994.
33. McClean J, Loehrer P, Picus J, Ansari R, Mitchell E, Reynolds R, Capizzi R. A Phase II Study of Altretamine for the Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology (HOG) Trial. Proceedings American Society of Clinical Oncology 13:763, 1994.
34. Capizzi RL, Scheffler B, Reynolds R, Mitchell E, Oster W, Schein PS. Hematologic Cytoprotection by Amifostine (WR-2721). 25th Congress on the International Society of Hematology, Cancun, Mexico. No. 64, 200, 1997.
35. Fox K, Glick J, Schulz J, Demers L, Connor G, Reynolds R, Mitchell E, Capizzi R, Schein R. Suppression of Estrogens and Possible Increased Clearance of Estrone Sulfate by Rogletimide (ROG) when used in the Treatment of Breast Cancer: Data from a Phase II Study. Proceedings American Society of Clinical Oncology
36. Mitchell EP, Li W, Koido T, Maruyama H, Rosato F, Barbot D, Haegele L, Kaufman A, Harris D, Mastrangelo M, Rose L, Bierman W, Comis R, Herlyn D. Modulation of Colorectal Cancer (CRC) Patients' Immune Responses by Monoclonal Anti-Idiotypic Antibody Mimicking the CO14-1A epitope. Proceedings American Society of Clinical Oncology 16:441a, 1997.
37. Admad NR, Anne PR, Nagle DA, Rose LJ, Mitchell EP, Fry RD. Preoperative Chemoradiation Therapy Appears Superior to Preoperative Radiation Alone in the Management of Clinical T3/T4 Rectal Cancer. Proceedings American Society of Clinical Oncology 17, 1997.
38. Petit RG, Rothenberg ML, Mitchell EP, Compton LD, Miller LL. Cholinergic Symptoms Following CPT-11 Infusion in a Phase II Multicenter Trial of 250 mg/M² Irinotecan (CRT-11) Given Every Two Weeks. For the CPT-11 Study Group. Proceedings American Society of Clinical Oncology 17, 1997.
39. O'Dwyer PJ, Stevenson JP, Gallager M, Mitchell E, Friedland D, Rose L, Casella A, Holmund J, Dean N, Dorr A, Geary R, Yao KS. Phase I/Pharmacokinetic/Pharmacodynamic Trial of Raf-1 Antisenseodn (ISIS 5132, CGP 69846A) Vol 17 Proceedings American Society of Clinical Oncology.
40. Rothenberg ML, Hainsworth JD, Rosen L, Mitchell EP, Henderson CA, Gralla RJ, Rivkin S, Hanson PJ, Feun LG, Petit RG, Compton LD, Pirota N, Elfring GL, Miller LL. Phase II Study of Irinotecan (CPT-11) 250 MG/M² Given Every-Other Week in previously treated colorectal cancer patients Vol 17 Proceedings American Society of Clinical Oncology.
41. Mitchell EP, Somasudaram R, Birebent R, Akis N, Li W, Nair S, Barbot D, Harris D, Mastrangelo M, Maguire H, Rose L, Rosato G, Bierman W, Herlyn D. Modulation of Colorectal Cancer (CRC) Patients Immune Responses by Monoclonal Anti-idiotypic Antibody Mimicking the Co17-1A Epitope. Vol 17 Proceedings American Society of Clinical Oncology.

42. Boman BM, Fry RD, Curran W, Rose DG, Bocker T, Kovatich A, Barusevicius A, Palazzo J, Cuesta K, Anne P, Melchert L, Fishel R, Mitchell E. Unique Immunohistochemical Features of MSI-Classified Tumors from HNPCC Patients Proceedings American Society of Clinical Oncology 18:236a, 1999.
43. Mitchell E, Ahmad N, Fry R, Anne PR, Rakinic J, Goldstein S, Rose L, Kaufmann A, Hightower M, Palazzo J, Boman B, Bonanni R, Hoey D, Curran WJ. Combined Modality Therapy of Locally Advanced or Recurrent Adenocarcinoma of the Rectum: Preliminary Report of a Phase I Trial of Chemotherapy (CT) with CPT-11, 5-FU and Concomitant Irradiation (RT). Proceedings American Society of Clinical Oncology 18:247a, 1999
44. Benson AB, Mitchell E, Abramson N, Klenke B, Ritch P, Burnham J, McGuirt C, Levin J, Hohnaker J. A Multicenter, Phase II Trial of Oral Eniluracil Plus 5-FU in Patients with Inoperable Hepatocellular Carcinoma. Proceedings American Society of Clinical Oncology 18:256a, 1999.
45. Anne PR, Mitchell EP, Rosato FE, Ahmad N, Kairys JC, Chapman AE, Bonanni R, Curran WJ. A Phase I Study of Preoperative Paclitaxel, carboplatin, 5-FU and Radiation in Patients with Resectable Esophageal or Gastric Cancer. Proceedings American Society of Clinical Oncology 18:277a, 1999.
46. Mitchell EP, McGruder S, Bayliss L, Bough W, Duckett J, Misse E, Partridge E, Williams B, Williamson O, Wrenn W, Green C, Marinucci D, Catalano RB, Comis RL. Increasing Participation By African-American Women In NCI-Sponsored Prevention Trials Involving Primary Care Physicians. Proceedings American Society of Clinical Oncology 21:194b, 2002.
47. Jacobs A, Planting A, Ferry D, Mitchell E, Evans TR, Hilke H, Hochster H. Knuth A, Schacter L, Donehower R. Efficacy of DHA-paclitaxel (TXP) in pancreatic cancer. American Society of Clinical Oncology, 2003.
48. Mitchell E, Anne PR, Fry R, Palazzo J, Hause W, Fishel R, Goldstein S, Isenberg G, Edmunston T, Curran W. Chemoradiation with CPT-11, 5FU in neoadjuvant treatment of locally Advanced or recurrent adenocarcinoma of the rectum: A phase I/II study update. American Society of Clinical Oncology, 2003.
49. Gams, RA, Ramanathan RK, Clark J, Kemeny N, Lenz, HJ, Gococo KO, Haller, DG, Mitchell E, Kardinal C. The oxiplatin treatment access program: Compassionate use experience of oxaliplatin as a single agent or in combination with 5-fluorouracil in more than 7000 patients with previously treated advanced colorectal cancer. American Society of Clinical Oncology, 2003.
50. Dold FG, Mitchell EP, Topham AK. Colorectal cancer in African-Americans and Caucasians: Results of a comparison at Thomas Jefferson University Hospital. American Society of Clinical Oncology, 2003.
51. Badarinath S, Mitchell EP, Jennis A, Graham CD, Hansen VL, Henderson CA, Chen TT, Langer C. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial, Journal of Clinical Oncology, Vol 22, No 15S (July 15 Supplement), 3531: 2004.

52. Mitchell EP, Winter K, Mohiuddin M, Hanna N, Yuen A, Nichols C, Share R, Hayostek C, Willett C. Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer. Journal of Clinical Oncology, Vol 22, No 14S (July 15 Supplement), 3535: 2004.
53. Meropol, NJ, Gold, PJ, Diasio, RB, Chen, YM, Godfrey, T, Hill, T, Kovatich, AJ, Lund, KA, Mitchell, E, Swarting, R. Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. Journal of Clinical Oncology, Vol 22, No 14S (July 15 Supplement), 3520: 2004.
54. Anne PR, Axelrod R, Rosato E, Rosato F, Kairys J, Ramirez M, Cantor R, Chapman A, Curran W, Mitchell E. A phase II trial of preoperative paclitaxel, carboplatin, 5-FU and radiation in patients with respectable esophageal or gastric cancer (Ca). Journal of Clinical Oncology, Vol 22, No 14S (July 15 Supplement), 4031: 2004.
55. Mitchell EP, Fleisher L, Spencer C, McKeown-Conn N, Gonzalez E, Hart-Minor B, Green C. Moving NMA Members to Action: The SPNCC/Region 2 NMA Project to increase use of NCI/CIS resources. Intercultural Cancer Council, 2004.
56. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mithcell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. American Society of Clinical Oncology, Abstract No 2, 2005.
57. Daluvoy S, Rosato EL, Cowan S, Rosato FE, Berger AC, Kairys JC, Rose L, Curran W, Anne PR, Mitchell EP. Neoadjuvant chemoradiotherapy with 5-fluorouracil, (5-FU), carboplatinum © and paclitaxil (T) dramatically improves survival in patients with clinical stage 2 and 3 adenocarcinoma of the distal esophagus and GE junction compared to surgery alone. American Society of Clinical Oncology, Abstract No 35, 2005.
58. Giantonio BJ, Catalano PJ, Meropol NJ, Mithcell EP, Schwartz MA, Alberts SR, O'Dwyer PJ, Benson AB. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. American Society of Clinical Oncology, Abstract No 169a, 2005.
59. Mitchell EP, Anne PR, Fry R, Palazzo J, Pequignot E, Fishel R, Goldstein S, Isenberg G, Edmundston T, Curran W. Improved local control with chemoradiation with CPT-11, 5FU in neoadjuvant treatment of locally advanced or recurrent adenocarcinoma of the rectum. American Society of Clinical Oncology, Abstract No 246, 2005.
60. Pitot HC, Rowland KM, Sargent DJ, Philip PA, Mitchell EP, Goldberg RM, Alberts SR. N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. American Society of Clinical Oncology, Abstract No 3506, 2005.
61. Rowland KM, Pitot HC, Sargent DJ, Philip PA, Mitchell EP, Mailliard JA, Goldberg RM, Alberts SR. Results of 3rd line therapy on N98941: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal

- cancer (CRC) previously treated with prior 5FU chemotherapy. American Society of Clinical Oncology, Abstract No 3519, 2005.
62. Jennis A, Polikoff J, Mitchell E, Badarinath S, Graham C, Chen T, Gustafson T, Langer, C. Erbitux (Cetuximab) Plus FOLFOX for Colorectal Cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial. American Society of Clinical Oncology, Abstract No 3574, 2005.
 63. Mitchell E, Marshall J, Chang J, Ganju V, Jeffery M, Schulz J, Richards D, Morrison M, Weisberg J, Fuchs C. Randomized phase III study of 3 irinotecan regimens in 1st-line metastatic colorectal cancer (CRC): safety/tolerability of irinotecan + oral capecitabine with or without celecoxib (BICC). American Society of Clinical Oncology, Abstract No 3652, 2005.
 64. Kim CS, Anne PR, Mitchell EP, Palazzo J, Pequignot E, Fishel R, Goldstein SD, Isenberg GA, Curran W. Tumor size as a predictor of pathologic complete response (pCR) and survival in a prospective trial of chemoradiation for locally advanced rectal cancer. American Society of Clinical Oncology, Abstract No 3672, 2005.
 65. Goldstein MJ, Leighton JC, Chapman A, Carberry M, Mitchell EP. Phase I trial of thalidomide and capecitabine for treatment of metastatic colorectal cancer. American Society of Clinical Oncology, Abstract No 3687, 2005.
 66. Morris GJ, Naidu S, Tomham A, McCue P, Schwartz G, Rosenberg A, Mitchell EP. Differenced in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients; a single-institution compilation compared with the National Cancer Institute SEER database. American Society of Clinical Oncology, Abstract No 9670, 2005.
 67. Fuch C, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schultz J, Richards D, Wang B, Morrison M. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). American Society of Clinical Oncology, Abstract No 3506, 2006.
 68. Cohen SJ, Terstappen LW, Punt CJ, Mitchell EP, Fynan TM, Matera LJ, Doyle GV, Meropol NJ. Circulating endothelial cells (CEC) and circulating tumor cells (CTC) in patients (pts) with metastatic colorectal cancer (mCRC). American Society of Clinical Oncology, Abstract No 3531, 2006.
 69. Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, D'Avirro,P, Amado R. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). American Society of Clinical Oncology, Abstract No 3547, 2006.
 70. Mitchell EP, Anne P, Goldstein S, Isenberg G, Fitzgerald J, Palazzo J, Hauck W, Lavarino J, Sansom J, Curran WJ. Combined modality therapy of locally advanced adenocarcinoma of the rectum: Update of a phase I trial of preoperative radiation (RT) with concurrent capecitabine (Cap) and irinotecan (Ir). American Society of Clinical Oncology, Abstract No 13547, 2006.
 71. Goldstein MJ, Leighton JC, Chapman A, Muskett A, Sharan K, Sansom J, Mitchell EP. Phase I trial of thalidomide and capecitabine for treatment of metastatic colorectal cancer. American Society of Clinical Oncology, Abstract No 13552, 2006.

72. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S, Benson III A. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). American Society of Clinical Oncology, Abstract No LBA4004, 2006.
73. Mitchell E, Hecht J, Baranda J, Malik I, Richards D, Navale L, D'Avirro P, Amado R. Pantirumumab in metastatic colorectal cancer patients with low/negative epidermal growth factor receptor levels. Annals of Oncology, Abstract No. PD-005, 2006.
74. Morris G, Naidu S, Topham A, Guiles F, Chervoneva I, McCue P, Schwartz G, Park P, Rosenberg A, Sabol J, Brill K, Mitchell E. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients; a single-institution compilation compared with the National Cancer Institute SEER database. San Antonio Breast Conference, 2006. (Poster Presentation)
75. Mohiuddin M, Garcia M, Mitchell E, Hanna N, Yuen A, Nichols C, Share R, Hayostek C, Willett C. 3-year results of RTOG-0012 randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Radiation Therapy Oncology Group, 2006. (Poster presentation).
76. Morris GJ, Mitchell EP. Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. Journal of the National Medical Association, 99:1, 2007.
77. Morris G, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients; a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer, 110:4, 2007.
78. Drelich DA, Rose L, Ramirez M, Jacobs M, Mitchell E. Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC) from three clinical studies. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14551.
79. Langerak AD, Mitchell E, Cheema P, River GL, Shing M. Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14579.
80. Catalano, PC, Mitchell EP, Giantonio, BJ, Meropol NJ, Benson, AB. Outcomes differences for African Americans and Caucasians treated with bevacizumab, FOLFOX4 or the combination in patients with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4100
81. Tubb, EE, Jacobs M, Mitchell EP. Response to the combination of cetuximab, bevacizumab and irinotecan (cetux/bev/iri) in patients (pts) previously treated with 3rd-line panitumumab, following disease progression on oxaliplatin, irinotecan and a fluoropyrimidine. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 14586.

82. Mitchell EP, Hecht JR, Baranda J, Malik I, Richards D, Reiner M, Stout S, Amado RG. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 4082.
83. Barrueco J, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schultz J, Richards D, Soufi-Mahjoubi R, Fuchs C. Safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 4076.
84. Fuchs C, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schultz J, Richards DA, Soufi-Mahjoubi R, Barreuco J. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: Updated efficacy data. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 4027.
85. Mitchell EP, Rose L, Ramirez M, Jacobs M. Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer from two clinical studies. Gastrointestinal Cancers Symposium, 2007: 449.
86. Cohen SJ, Punt CJ, Iannotti N, Saidman, BH, Sabbath KD, Mitchell EP, Miller C, Doyle GV, Terstappen LW, Meropol NJ. Monitoring patients with metastatic colorectal cancer using circulating tumor cells. Gastrointestinal Cancers Symposium, 2007: 342.
87. Hecht JR, Mitchell EP, Baranda J, Malik I, Richards D, Reiner M, Stout S, Amado R G. Panitumumab activity in metastatic colorectal cancer patients with low or negative tumor epidermal growth factor receptor levels: An updated analysis. Gastrointestinal Cancers Symposium, 2007: 350.
88. Fuchs CS, Marshall J, Mitchell EP, Wierzbicki R, Ganju V, Jeffery M, Schultz J, Richards D, Soufi-Mahjoubi R, Barrueco J. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations ± celecoxib in mCRC: Clinical data cut-off September 1, 2006. Gastrointestinal Cancers Symposium, 2007: 276.
89. Burtness BA, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson AB, Eastern Cooperative Oncology Group. Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r): Eastern Cooperative Oncology. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 4519.
90. Hecht JR, Mitchell EP, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall JL, Cohn A, Shahin S, Griffin T. An updated analysis of safety and efficacy of oxaliplatin/bevacizuman +/- panitumumab for first-line treatment of metastatic colorectal cancer from a randomized controlled trial (PACCE). Gastrointestinal Cancers Symposium, 2008: 273.

91. Hecht JR, Mitchell EP, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall JL, Cohn A, Suzuki S, Griffin T. Interim results from PACCE: Irinotecan/bevacizumab ± panitumumab for first-line treatment of metastatic colorectal cancer. Gastrointestinal Cancers Symposium, 2008: 279.
92. Mitchell EP, Polikoff J, Badarinath S, Jennis A, Labroschiano A, Awad M, Lu H, Langer C, Khambata-Ford S. Analysis of *K-RAS* Mutation status and EGFR gene copy number in the EXPLORE study: FOLFOX4 vs. FOLFOX4/cetuximab in previously treated metastatic colorectal cancer. Gastrointestinal Cancers Symposium, 2008: 306.
93. Hecht JR, Mitchell EP, Baranda J, Richards D, Reiner M, Stout S, Amado RG. Panitumumab efficacy in patients with metastatic colorectal cancer with low or undetectable levels of epidermal growth factor receptor: Final efficacy and *KRAS* analyses. Gastrointestinal Cancers Symposium, 2008: 343.
94. Mitchell EP, LaCouture M, Shearer H, Iannotti N, Piperdi B, Pillai MV, Xu F, Couture M, Yassine M. A phase II, open-label, randomized clinical trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer patients receiving 2nd line FOLFIRI or irinotecan-only chemotherapy with panitumumab: Early analysis. Gastrointestinal Cancers Symposium, 2008: 462.
95. Tubbee, Nugent M, Spielberger J, Axelrod RA, Mitchell EP. Abnormal hair growth in patients with metastatic colorectal cancer treated with the anti-epidermal growth factor receptor monoclonal antibody panitumumab. Journal of Clinical Oncology, 26: 2008 (May 20 Suppl; Abstract 15065).
96. Mitchell EP, LaCouture ME, Shearer H, Iannotti N, Piperdi B, Pillai MV, Xu F, Couture M, Yassine M. A phase II, open-label trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer patients receiving panitumumab + FOLFIRI or irinotecan-only chemotherapy as 2nd-line treatment: Interim analysis. Journal of Clinical Oncology, 26: 2008 (May 20 Suppl; Abstract 15007).
97. Wong SJ, Winter K, Meropol NJ, Anne R, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Willett CG. RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Journal of Clinical Oncology, 26: 2008 (May 20 Suppl; Abstract 4021).
98. Burtness BA, Powell ME, Berlin JD, Liles DK, Chapman AE, Mitchell EP, Benson AB. Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19-9 results. Journal of Clinical Oncology, 26: 2008 (May 20 Suppl; Abstract 4642).
99. Kubicek G, Berger AC, Rosato EL, Kennedy EP, Lin A, Mitchell E, Yeo C, Anne R. Role of Radiotherapy in the Treatment of Duodenal Adenocarcinoma. Radiographic Society of North America, 2008 (Abstract 6017480).
100. Mitchell EP, Maron S, Topham A, Guiles F, Goldstein S, Isenberg G, Anne PR, Palazzo J. Colorectal cancer in patients under age 50: Characteristics and outcomes. Gastrointestinal Cancers Symposium, 2009: (Abstract 305).
101. Mitchell EP, Singla R, Topham A, Guiles F, Goldstein S, Anne PR, Isenberg G, Maxwell JP, Palazzo J. Differences in colorectal disease in African-American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. Gastrointestinal Cancer Symposium, 2009: (Abstract 306).

102. Showalter SL, Rosato EL, Anne PR, Scott W, Mitchell E, Berger AC. Does diabetes mellitus influence pathologic complete response and tumor downstaging after neoadjuvant chemoradiation for esophageal and gastroesophageal cancer? A two-institution report. Journal of Surgical Oncology, 2010 Jan 1 101(1):43-6.
103. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 2010 Mar 10 28(8):1351-7.
104. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clinical Cancer Research, 2010 Apr 1 16(7):2205-13.
105. Noto KA, Almario C, Maxwell PJ, Mitchell EP, Isenberg GA, Goldstein SD. Long-term survival after colonic stenting and restenting for malignant colonic obstruction. Am Surg, 2010 Apr 76(4):457-9.
106. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biology & Therapy, 2010 Jul 10(2):135-43.
107. Gonsalves CF, Mitchell EP, Brown DB. Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer. AJR American Journal of Roentgenol, 2010 Nov 195(5):1241-4.
108. Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, Berger AC. Do Elderly Patients Experience Increased Perioperative or Postoperative Morbidity or Mortality When Given Neoadjuvant Chemoradiation Before Esophagectomy? Int J Radiat Oncol Biol Phys, 2010 Nov 22.
109. Pappas AP, Sen U, Intenzo CM, Schwartz GF, Mitchell EP, Lee S, Kim SM, Rosenberg AL, Utility of SUV max in axillary lymph node metastases in the initial staging of invasive breast carcinoma. ACNM/SNM Mid-Winter Symposium, 2011.
110. Showalter TN, Zhan T, Anne PR, Chervoneva I, Mitchell EP, Yeo CJ, Rosato EL, Kennedy EP, Berger AC. The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma. Journal Gastrointestinal Surgery, 2011 Apr 27.
111. Gray NM, Hall SJ, Browne S, Macleod U, Mitchell E, Lee AJ, Johnston M, Wyke S, Samuel L, Weller D, Campbell NC. Modifiable and fixed factors predicting quality of life in people with colorectal cancer. British Journal of Cancer. 2011 May 10.
112. Mitchell EP, Topham A, Singla R, Maron S, Schoenfeld J, Guiles F, Goldstein S, Anne PR, Isenberg G, Maxwell PJ, IV. Racial disparity trends in clinical presentation and outcomes in colorectal cancer: Findings from an urban university hospital. J Clin Oncol 29: 2011 (suppl 4; abstr 518).

113. Cutsem E, Van, Eng C, Tabernero J, Nowara E, Swieboda-Sadlej A, Tebbutt N C, Mitchell E P, Davidenko I, Chen L, Smethurst D. A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab compared with panitumumab alone in patients with wild-type *KRAS* metastatic colorectal cancer: Safety and efficacy results. J Clin Oncol 29: 2011 (Suppl 4; Abstr 366).
114. Mitchell EP, Topham A, Singla R, Maron S, Schoenfeld J, Guiles F, Goldstein S, Anne PR, Isenberg G, Maxwell PJ, Palazzo J. Colorectal cancer in African American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. J Clin Oncol 29: 2011 (suppl; abstr 3631).
115. Mahipal A, Rosato E, Littman S J, Hargrove H, Bapat A R, Doria C, Mitchell E P. Gemcitabine, oxaliplatin, and bevacizumab (GEMOX-B): A promising regimen for the treatment of advanced biliary tract cancers. J Clin Oncol 29: 2011 (Suppl 4; Abstr 355).
116. Witkiewicz AK, Kline J, Mitchell E, Ertel A, Knudsen ES. Loss of the Retinoblastoma Tumor Suppressor (RB) in Triple Negative Breast Cancer is Associated with a Favorable Prognosis. San Antonio Breast Cancer Symposium, 2011: (Abstract PD10-06).
117. Eberhardt JS, Hyslop T, Mitchell E, Hu H, Rui H. Bayesian Belief Network Mortality Analysis of a Breast Cancer Registry Data Set. San Antonio Breast Cancer Symposium, 2011: (Abstract P5-14-12).
118. Intenzo CM, Mitchell EP, Litman S, Kim SM, Bar-Ad V. Is FDG-PET/CT useful in the staging and restaging of cholangiocarcinoma? Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, December 2011.
119. Intenzo CM, Sen U, Mitchell EP, Littman S, Kim SM. Is FDG-PET/CT sensitive in detecting metastases from hepatocellular carcinoma? Proceedings of the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, December 2011.
120. Channappa C, Intenzo CM, Kim SM, Mitchell EP, Littman S. The use of FDG-PET/CT imaging in follow-up of pancreatic cancer. Proceedings of the 2012 Annual Meeting of the American College of Nuclear Medicine. Orlando, FL, January 2012.
121. Pappas AP, Kim SM, Intenzo CM, Mitchell EP. Response assessment of colorectal liver metastases with PET/CT, MRI, and CT: an intermodality comparison. Proceedings of the 2012 Annual Meeting of the American College of Nuclear Medicine. Orlando, FL, January 2012.
122. Ocean AJ, Guarino MJ, Pennington KL, Springett GM, Gulec SA, Bekaii-Saab TS, Montero AJ, Mitchell EP, Kauh JS, Sung MW, Gold DV, Horne H, Wegener WA, Goldenberg DM. Phase I/II study of ⁹⁰Y-clivatuzumab tetraxetan (⁹⁰Y-hPAM4) combined with gemcitabine in advanced pancreatic cancer: Final results. J Clin Oncol 30, 2012 (Suppl; Abstr 4043).
123. Mitchell EP, Topham A, Anne PR, Goldstein S, Isenberg G, Guiles F, Palazzo J. Colorectal cancer characteristics and outcomes in patients less than age 50: A comparison of an urban university hospital with the NCI SEER database. J Clin Oncol 30, 2012 (Suppl; Abstr 3621).
124. Ocean AJ, Guarino MJ, Pennington KL, Springett GM, Gulec SA, Bekaii-Saab TS, Montero AJ, Mitchell EP, Kauh JS, Sung MW, Gold DV, Horne H, Wegener WA, Goldenberg DM. Activity of

- fractionated radioimmunotherapy with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine in advanced pancreatic cancer: Final results from a two-part study. J Clin Oncol 30, 2012 (Suppl 4; Abstr 227).
125. Valsecchi ME, Littman SJ, Holdbrook T, Leiby B, Mitchell EP, Yeo C, Brody JR, Witkiewicz A. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? J Clin Oncol 30, 2012 (Suppl 4; Abstr 246).
126. Littman SJ, Monti D, Newberg A, Bazzan A, Pillai MV, Lewis N, Yeo C, Levine M, Mitchell EP. A phase I open-label, dose-escalation study of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 30, 2012 (Suppl 4; Abstr 323).
127. Zhao F, Chang VT, Cleeland C, Cleary JF, Mitchell EP, Patterson E, Wagner LI, Fisch MJ. Determinants of pain changes in ambulatory cancer patients by baseline pain severity: An analysis from ECOG E2Z02 (SOAPP Study). MASCC Annual Meeting, Supp Care Cancer 2012; 20 (Suppl 1); S151: (abstr 638).
128. Chang VT, Zhao F, Tevaarwerk A, Mitchell EP, Patterson E, Ritchie C, Manola J, Wagner LI, Fisch MJ. Determinants of driving in cancer patients: an analysis for SOAPP (ECOG E2Z02: Symptom Outcomes and Practice Patterns). MASCC Annual Meeting, Supp Care Cancer 2012; 20 (Suppl 1): S151 (abstr 639).
129. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012; 7 (1): e29794.
130. Mitchell EP, Guarino MJ, Andria ML, Bhargava P, Kirshner JJ. North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. J Clin Oncol 31, 2013 (suppl; abstr e14528).
131. Mitchell EP, Guarino MJ, Allegra CJ, Boelle E, Andria ML, Bhargava P, Kirshner JJ. North American subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. J Clin Oncol 31, 2013 (suppl 4; abstr 465).
132. Avery TP, Berger AC, Kovatich AJ, Rui H, Hyslop T, Mitchell EP. An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS1135).
133. Starodub A, Thomas SP, Lee FC, Harish V, Koh HA, Mitchell EP, Mandanas RA, Huh SY, Badarinath S, Mittan A, Leon L, Vogt T, Langer C, Lenz HJ. Biomarker distribution and characteristics for the first 100 patients in MAVERICC, a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously untreated metastatic colorectal cancer. J Clin Oncol 31, 2013 (suppl 4; abstr 483^).

134. Littman SJ, Knudsen ES, Witkiewicz A, Hyslop T, Lewis N, Pillai MV, Brus C, Mitchell EP. A phase II study of PD-0332991 in patients with advanced hepatocellular cancer. J Clin Oncol 31, 2013 (suppl 4; abstr 321).
135. Rodriguez J, Limentani K, Andrel-Sendecki J, Hyslop T, Cristofanilli M, Jaslow RJ, Avery TP, Mitchell EP. Breast cancer in young women: A single center study. J Clin Oncol 32:5s, 2014 (suppl; abstr 595).
136. Mitchell EP, Catalano PJ, Giantonio BJ, O'Dwyer PJ, Meropol NJ, Benson AB, Hamilton SR. CpG island methylator phenotype and outcome differences for African Americans and Caucasians treated with FOLFOX4 or the combination with bevacizumab in patients with metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 32:5s, 2014 (suppl; abstr 3605).
137. Hochster HS, Catalano PJ, Mitchell EP, Cohen DJ, O'Dwyer PJ, Benson AB. E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab in second-line therapy of KRAS wild-type colorectal cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3665).
138. Hoff PM, Hazel GV, Cunningham D, Arnold D, Schmoll H, Ten Tije AJ, Naoshy S, Joulain F, McKendrick J, Vishwanath RL, Dochy E, Mitchell EP. The consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the velour trial stratified by first-line progression ≥ 9 months versus < 9 months. J Clin Oncol 32:5s, 2014 (suppl; abstr 3639).
139. Cohen SJ, Feng Y, Catalano PJ, Mitchell EP, O'Dwyer PJ, Lubner SJ, Fisher GA, Mulcahy MF, Burtness B, Benson AB. E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 4020).
140. Asija A, Sama AR, Casey J, Andrel-Sendecki J, Lewis N, Lavu H, Winter JM, Brody JR, Mitchell EP, Yeo C, Prestipino A, Pillai MV. A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors. J Clin Oncol 32, 2014 (suppl; abstr e15170).
141. Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchell EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braithe FS, Lee FC, Gribbin TE, Richards DA, Starodub A, Wegener WA, Goldenberg DM. Feasibility and results of a randomized phase Ib study of fractionated ^{90}Y -clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. J Clin Oncol 32:5s, 2014 (suppl; abstr 4026).
142. Gooptu M, Doval D, Kumar K, Dewan A, Mehta A, Batra U, Dutta K, Avery TP, Jaslow RJ, Mitchell EP, Naiyer A, Manavalan J, Cristofanilli M. Breast cancer in low-income countries: India as a model. J Clin Oncol 32, 2014 (suppl; abstr e17517).
143. Katz MS, Topham A, Manola J, Scroggins MJ, Smith ML, Mitchell EP, Catalano RB, Marinucci DM, Giantonio BJ, Comis RL. Medically Underrepresented Populations in National Cancer Institute Sponsored Cancer Clinical Trials: Refining the Calculation of Accrual Targets. J Clin Oncol 33, 2015 (suppl; abstr e17598).

144. Sama AR, Asija A, Casey J, Andrel-Sendecki J, Lewis N, Lavu H, Winter JM, Brody JR, Mitchell EP, Yeo C, Prestipino A, Pillai MV. A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors. *J Clin Oncol* 33, 2015 (suppl 3; abstr 267).
145. Hochster HS, Catalano PJ, Mitchell EP, Cohen DJ, O'Dwyer PJ, Benson AB. E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab in second line therapy of KRAS wild type colorectal cancer. *J Clin Oncol* 33, 2015 (suppl 3; abstr TPS793).
146. Yeung V, Gong Y, Yu J, Yu Y, Lu B, Palmer JD, Burkhart R, Leiby BE, Siow VS, Lavu H, Rosato E, Winter JM, Lewis N, Sama AR, Mitchell EP, Anne PR, Xiao, Hurwitz M, Yeo C, Bar-Ad V. Predicting overall survival for patients with periampullary carcinoma. *J Clin Oncol* 33, 2015 (suppl 3; abstr 376).
147. Eng C, Cutsem EV, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell EP, Davidenko I, Lee O, Smith-Oliner K, Schupp M, Loh E, Sidhu R, Tabernero J. Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab or ganitumab plus panitumumab (pmab) versus pmab alone in patients with previously treated metastatic colorectal cancer. *J Clin Oncol* 33, 2015 (suppl 3; abstr 694).
148. Lenz HJ, Lee FC, Yau L, Koh HA, Knost JA, Mitchell EP, Bosanac I, Mancao C, Parikh A. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs. FOLFIRI-BV with biomarker stratification as first-line chemotherapy in patients with metastatic colorectal cancer. *J Clin Oncol* 34, 2016 (suppl 4S; abstr 493).
149. Bailey M, Mitchell EP, Morosini D, Lipson D, Ross JS, Miller VA, Jie He, Stephens P. Comprehensive genomic profiling in colorectal cancer to identify differing frequencies of clinically relevant genomic alterations in tumors of patients less than age 50 as compared to those of patients over age 65. *J Clin Oncol* 34, 2016 (suppl 4S; abstr 570).
150. Conley BA, Chen AP, O'Dwyer PJ, Arteaga CL, Hamilton SR, Williams PM, Little RF, Takebe N, Patton D, Sazali K, Zhang J, Zwiebel JA, Mitchell EP, Gray RJ, McShane L, Li S, Rubinstein L, Flaherty K, NCI MATCH team. NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial. *J Clin Oncol* 34, 2016 (suppl; abstr TPS2606).
151. Lenz HJ, Lee FC, Yau L, Koh HA, Knost JA, Mitchell EP, Bosanac I, Mancao C, Parikh A. MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line chemotherapy in patients with metastatic colorectal cancer: Outcomes by tumor location and KRAS status. *J Clin Oncol* 34, 2016 (suppl; abstr 3515).
152. Garg M, Zhao F, Lee JY, Sparano JA, Palefsky J, Henry DH, Wachsman W, Rajdev L, Abouafia DM, Ratner L, Kachnic LA, Mitchell EP, Onitilo AA, Mitsuyasu RT, Benson AB. Phase II trials of cetuximab plus combined modality therapy in squamous cell carcinoma of the anal canal with and without human immunodeficiency virus infection. *J Clin Oncol* 34, 2016 (suppl; abstr 3522).
153. Benson AB, Zhao F, Meropol NJ, Catalano PJ, Chakravarthy B, Flynn PJ, Catalano RB, Giantonio BJ, Mitchell EP, Haller DG, Leichman CG, Petrelli NJ, Sinicrope FA, Tepper JE, Brierley JD, Sigurdson ER, Whittington RM, O'Dwyer PJ. Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab for patients

- with stage II/ III rectal cancer receiving pre-operative chemoradiation. J Clin Oncol 34, 2016 (suppl; abstr 3616).
154. Mitchell EP, Dornsife D. Impact of financial burden on information and opportunity for cancer patients' participation in clinical trials. J Clin Oncol 34, 2016 (suppl 26S; abstr 166).
155. Salama April KS, Li Shuli, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane L, Rubinstein L, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty K. Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. J Clin Oncol 37, 2019 (suppl; abstr 3002).
156. Au C, Gupta E, Khaing P, DiBello J, Chengsupanimit T, Mitchell EP, West F, Baram M, Awsare BK, Kane GC. Impact of cancer in pulmonary embolism presentation and outcomes: A large academic center study. J Clin Oncol 37, 2019 (suppl; abstr 6613).
157. Subramoney J, Delgado DJ, Nguyen V, Denny RG, George B, Mitchell EP. Histology and stage at presentation among patients with rare pancreatic tumors: An exploratory analysis of the SEER database. J Clin Oncol 37, 2019 (suppl; abstr e15774).
158. Nguyen V, Delgado DJ, Denny RG, Subramoney J, George B, Mitchell EP. Urban/rural disparities in stage at presentation of colorectal cancer among young adults in the United States, 2007-2015. J Clin Oncol 37, 2019 (suppl; abstr 3598).
159. Denny RG, Delgado DJ, Nguyen V, George B, Mitchell EP, Subramoney J. Stage of disease and initial surgical intervention in colon cancer patients: An exploratory analysis of the SEER database. J Clin Oncol 37, 2019 (suppl; abstr e15170).
160. Chen AP, Li S, Coffey B, Tricoli JV, Hamilton SR, Williams MP, Mitchell EP, Patton D, Gray RJ, McShane LM, Rubinstein LV, Arteaga CL, O'Dwyer PJ, Harris LN, Conley BA, Flaherty KT. Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131). Molecular Cancer Therapeutics 2019;18 (12) (suppl; abstract A089).
161. Harris LN, Gray RJ, Conley BA, Chen AP, Flaherty KT, Hamilton SR, Williams PM, Karlovich C, Patton D, Li S, McShane LM, Rubinstein LV, Mitchell EP, Tricoli JV, Little RF, Arteaga CL, O'Dwyer PJ, NCI-MATCH Team. National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): a successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies. Molecular Cancer Therapeutics, 2019;18 (12 Suppl): Abstract A079.
162. Starks V, Mitchell EP. Associations between oncogenic risk markers and clinical outcomes among black and white colorectal cancer patients. J Clin Oncol 38: 2020 (suppl; abstr e16078).
163. Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Doyle LA, Gray RJ, Li S, McShane L, Rubinstein LV, Patton DR, Williams M, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty K. Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. J Clin Oncol 38: 2020 (suppl; abstr 3506).

164. Mita AC, Wei Z, Mayer IA, Cheng H, Mitchell EP, Wright JJ, Ivy SP, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty, KT. Erdafitinib in patients with tumors harboring *FGFR* gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. October 2021.
165. Vaughan-Briggs C, Mitchell EP, Pepe V. An update to a retrospective comparison of results between the National Breast and Cervical Cancer Early Detection Program and NCI cancer center based early detection program with evidenced based patient navigation and social work support. 2022 ASCO Annual Meeting Proceedings. (June Supplement), 2022: 361171.

Monographs:

1. 2000 Eastern Cooperative Oncology Group, "*African-American Women CAN Beat Breast Cancer.*" Breast cancer awareness and prevention education video.
2. 2004 Genentech BioOncology, "*The Colon Cancer Puzzle: Putting all the right pieces together to beat it.*" Colorectal cancer awareness and prevention education video.
3. 2005 Pfizer, Inc., "*Pfizer Facts: Racial Differences in Cancer. A Comparison of Black and White Adults in the United States.*" Disparities Book.
4. 2005 Sanofi Aventis, "*Solving Treatment and Toxicity Dilemmas in Advanced Gastricancer.*" CME Monograph.
5. 2006 Medical Crossfire, "*Focus on Advanced Gastric Cancer: The Search for a New Standard of Care.*" CME Certified Monograph.
6. 2006 Pfizer, Inc., "*Colorectal Cancer Pathways: A Resource Guide for the Patient Navigator.*" A book included in the Patient Navigation in Cancer Care Toolkit.
7. 2007 CMPMedica, E-Updates Quarterly Newsletter, "*Targeted Therapy in Colorectal Cancer.*"
8. 2007 Pfizer Oncology, Optimizing Treatment Strategies in Colorectal Cancer Series, "*Tailoring Treatment for Metastatic Colorectal Cancer: Considerations for first-line therapy.*"
9. 2008 Oncology Unplugged Podcast Interview Series: *Highlights From the 2008 Society of Surgical Oncology Annual Meeting* Multidisciplinary Advances in the Management of Gastrointestinal Cancer: Implications for Surgical Oncologists. An Interview with Edith Mitchell, MD, Conducted by Axel Grothey, MD.
10. 2017 *CancerCare. Patient Values Initiative: The Many Voices of Value, A CancerCare Focus Group Assessment.* New York: CancerCare.
11. 2018 *Sickle Cell Disease Council for CHANGE: Improving Vaso-occlusive Crisis Management.* Council for Change.

Lectures:

1. January, 2004 - San Antonio, TX “New Treatment Paradigms in Colorectal Cancer.”
2. January, 2004 – Austin, TX “New Treatment Paradigms in Colorectal Cancer.”
3. January, 2004 – Dallas, TX “New Treatment Paradigms in Colorectal Cancer.”
4. January, 2004 – West Orange, NJ “New Treatment Paradigms in Colorectal Cancer.”
5. February, 2004 – Bloomington, MN “New Treatment Paradigms in Colorectal Cancer.”
6. March, 2004 – Reading, PA “Targeted Agents in the Management of Colorectal Cancer.”
7. March, 2004 – Providence, RI “Advances in the Management of Colorectal Cancer.”
8. March, 2004 – Bethesda, MD “Disparities in Cancer Outcomes Among African Americans.”
9. April, 2004 – Anaheim, CA “Treatment of Metastatic Colorectal Cancer.”
10. May 2004 – St. Louis, MO “Cetuximab: A New Targeted Cancer Therapy.”
11. May 2004 - Wynnwood, PA “Recent Advances in Colorectal Cancer: Angiogenesis Inhibitors.”
12. May 2004 – Upland, PA “Recent Advances in Colorectal Cancer: Angiogenesis Inhibitors.”
13. May 2004 – Newark, NJ “Colorectal Cancer: Update 2004.”
14. June, 2004 – Pittsburgh, PA “Advances in the Management of Colorectal Cancer.”
15. May, 2005 – White Sulphur Springs, WV “Disparities in Colorectal Cancer Treatment.”
16. September, 2005 – Washington, DC – CME Lecture Series “Solving Treatment and Toxicity Dilemmas in Advanced Gastric Cancer.”
17. October, 2005 – Washington, DC ““Update on Colorectal Cancer.””
18. January, 2006 – State College, PA “New Developments in the Treatment of Colorectal Cancer.”
19. February, 2006 – Baltimore, MD “Health Disparities in Cancer.”
20. February, 2006 – Annapolis, MD “New Treatment Paradigms in Colorectal Cancer.”
21. March, 2006 – Scottsdale, AZ “Therapeutic Advances in Treatment of GI Malignancies.”
22. March, 2006 – Princeton, NJ “Treatment of Metastatic Colorectal Cancer.”

23. March, 2006 – Farmington, PA “Disparities in the Treatment of Colorectal Cancer.”
24. April, 2006 – Suffern, NY “Colorectal Cancer Update: 2006.”
25. April, 2006 – Phoenix, AZ “New Advances in the Treatment of Colorectal Cancer and GI Malignancies.”
26. April, 2006 – Bethlehem, PA “Treatment of Metastatic Colorectal Cancer.”
27. April, 2006 – Perkasi, PA “Treatment of Metastatic Colorectal Cancer; Common Adverse Events and How to Treat Them.”
28. April, 2006 – Philadelphia, PA American College of Physicians.
29. May, 2006 – Toronto, Ontario – “Controversies in Rectal Cancer.”
30. May, 2006 – Center Valley, PA “Treatment of Metastatic Colorectal Cancer.”
31. May, 2006 – Easton, PA “New Advances in the Treatment of Colorectal Cancer.”
32. June, 2006 – Barcelona, Spain The 8th World Congress on Gastrointestinal Cancer.
33. June, 2006 – Reston, VA The Best of ASCO Meeting “Gastrointestinal (Colorectal) Cancer.”
34. July, 2006 – Dallas, TX “Treatment of Metastatic Colorectal Cancer.”
35. July, 2006 – Chicago, IL “Treatment of Metastatic Colorectal Cancer.”
36. August, 2006 – Dallas, TX “Getting Together to Beat Colorectal Cancer: Disparities in Colorectal Cancer.”
37. August, 2006 – New York, NY “New Advances in Targeted Therapy for Metastatic Colorectal Cancer.”
38. August, 2006 – Arlington, VA 2006 International Society of Gastrointestinal Oncology Conference “Advances in Therapy in Colorectal and Gastric Cancer.”
39. September, 2006 – Wilmington, DE “Targeting VEGF in Metastatic Colorectal Cancer.”
40. September, 2006 – Richmond, VA “Eloxatin[®] (Oxaliplatin Injection) in Combination with Infusional 5-FU/LV: A Standard in the Treatment of Advanced Colorectal Cancer and Adjuvant Treatment of Stage III Colon Cancer.”
41. September, 2006 – Wayne, PA “Treatment of Metastatic Colorectal Cancer.”
42. October, 2006 – Bethesda, MD “Targeting VEGF in Metastatic Colorectal Cancer.”

43. October, 2006 – Naples, FL Fifth International Colorectal Cancer Congress “Update on Radiation Therapy Oncology Group.”
44. October, 2006 – Fredrick, MD “Targeting VEGF in Metastatic Colorectal Cancer.”
45. October, 2006 – Philadelphia, PA “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
46. October, 2006 – Schenectady, NY “Exploring Multidisciplinary Advances in Colorectal Cancer Treatment.”
47. October, 2006 – Philadelphia, PA “Treatment Advances Using Eloxatin® (Oxaliplatin Injection).”
48. October, 2006 – Detroit, MI “New Advances in Targeted Therapy for Metastatic Colorectal Cancer.”
49. October, 2006 – Hyde Park, NY “Metastatic Colorectal Cancer.”
50. October, 2006 – New York, NY 2nd Annual Oncology Congress “NeoAdjuvant/Chemotherapy Treatment for Metastatic Colorectal Cancer.”
51. October, 2006 – Cooperstown, NY “Exploring Multidisciplinary Advances in Colorectal Cancer Treatment.”
52. November, 2006 – Newark, NJ “New Advances in Targeted Therapy for Metastatic Colorectal Cancer.”
53. November, 2006 – West Chester, PA “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
54. November, 2006 – Philadelphia, PA “Metastatic Colorectal Cancer: Integrating Biologics into Treatment Strategies.”
55. November, 2006 – Philadelphia, PA “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
56. December, 2006 - Columbia, MD “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
57. December, 2006 – Paramus, NJ “Treatment of Metastatic Colorectal Cancer.”
58. December, 2006 – Philadelphia, PA “Treatment Advances Using Eloxatin® (Oxaliplatin Injection).”
59. December, 2006 – Washington, DC “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
60. December, 2006 – Philadelphia, PA “Treatment of Metastatic Colorectal Cancer.”

61. December, 2006 - Pikesville, MD “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
62. December, 2006 – Pittsburgh, PA New Advances in Targeted Therapy for Metastatic Colorectal Cancer.”
63. December, 2006 - Hagerstown, MD “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
64. January, 2007 – Philadelphia, PA “Camptosar.”
65. February, 2007 – Gladwyne, PA “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
66. February, 2007 – Berwyn, PA “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
67. March, 2007 – Philadelphia, PA “Exploring Multidisciplinary Advances in Colorectal Cancer Treatment.”
68. March, 2007 – Philadelphia, PA “Targeting VEGF in Metastatic Colorectal Cancer: An Overview of Avastin® (bevacizumab).”
69. March, 2007 – Providence, RI Rhode Island Colorectal Cancer; “Overview of Treatment for Advanced Colorectal Cancer.”
70. March, 2007 - Farmington, PA “Disparities in the Treatment of Colorectal Cancer.”
71. March, 2007 – Philadelphia, PA “Update 2007: Treatment of Metastatic Colorectal Cancer.”
72. March, 2007 – Philadelphia, PA “Vectibix (panitumumab) Clinical Update Overview.”
73. March, 2007 – Minneapolis, MN “New Advances in Targeted Therapy for Colorectal Cancer.”
74. April, 2007 – Clinton, MD “Targeting VEGF in Metastatic Colorectal Cancer: An Overview of Avastin® (bevacizumab).”
75. April, 2007 – Washington, DC Howard University Grand Rounds; “Disparities in the Treatment of Colorectal Cancer.”
76. April, 2007 – Meadowbrook, PA “Optimizing Treatment Outcomes: Update of Evidence-based Strategies Every Practice Should Follow.”
77. May, 2007 – Atlanta, GA “Cancer Talk Live.”
78. May, 2007 - Dallas, TX “Evolving Role of Targeted Therapy: Focus on Colorectal Cancer.”
79. May, 2007 – Long Beach, CA MN “New Advances in Targeted Therapy for Colorectal Cancer.”

80. May, 2007 – Berwyn, PA “Vectibix (panitumumab) Clinical Update Overview.”
81. May, 2007 – Philadelphia, PA “Vectibix (panitumumab) Clinical Update: Emerging Trends in the Treatment of Metastatic Colorectal Cancer.”
82. May, 2007 – Philadelphia, PA, “Eloxatin in Combination with Infusional 5-FU/LV a Standard in the Treatment of Advanced Colorectal Cancer and Adjuvant Treatment of Stage III Colon Cancer.”
83. June, 2007 – Ephrata, PA “Vectibix (panitumumab) Clinical Update Overview.”
84. June, 2007 – Jacksonville, FL “The Evolving Role of Targeted Therapy: Focus on Colorectal Cancer.”
85. June, 2007 - Barcelona, Spain The 9th World Congress on Gastrointestinal Cancer.
86. July, 2007 – Moosic, PA “Vectibix (panitumumab) Clinical Update Overview.”
87. July, 2007 - Philadelphia, PA “Advances in the Diagnosis and Management in Colorectal Cancer.”
88. August, 2007 – Sacramento, CA “Vectibix (panitumumab) Clinical Update Overview.”
89. August, 2007 – New Brunswick, NJ “The Evolving Role of Targeted Therapy: Focus on Colorectal Cancer.”
90. August, 2007 – Fairfax, CA “Vectibix (panitumumab) Clinical Update Overview.”
91. September, 2007 – Arlington, TX “A Treatment Continuum in Metastatic Colorectal Cancer: Strategic Approach to Extend Survival.”
92. September, 2007 – State College, PA “Multidisciplinary Advances in Colorectal Cancer Treatment.”
93. September, 2007 – Philadelphia, PA “Vectibix (panitumumab) Clinical Overview.”
94. September, 2007 – Detroit, MI “New Advances in Targeted Therapy for Colorectal Cancer.”
95. September, 2007 – Bethesda, MD “Advances in the Diagnosis and Management of Colorectal Cancer.”
96. September, 2007 – Hollidaysburg, PA “Multidisciplinary Advances in Colorectal Cancer Treatment.”
97. September, 2007 – Grosse Pointe Woods, MI “The Continuum of Care in Colorectal Cancer.”
98. September, 2007 – Lansing, MI Michigan State University Grand Rounds; “Treatment of Metastatic Colorectal Cancer.”
99. September, 2007 – New York, NY Upper GI Malignancies Symposium “Chemotherapy for Advanced Gastric Cancer.”

100. October, 2007 - Syracuse, NY “The Evolving Role of Targeted Therapy.”
101. October, 2007 – Bryn Mawr, PA “Vectibix (panitumumab) Clinical Overview.”
102. October, 2007 – Memphis, TN “The Continuum of Care in Colorectal Cancer.”
103. October, 2007 – Livingston, NJ “Practical Utility of Positron Emission Tomography (PET) and PET/Computerized Tomography (CT) in Oncologic Patient Management.”
104. October, 2007 – Philadelphia, PA “Vectibix (panitumumab) Clinical Overview.”
105. October, 2007 – Galloway, NJ “Treatment of Metastatic Colorectal Cancer.”
106. November, 2007 - Manchester , CT “The Continuum of Care in Colorectal Cancer.”
107. November, 2007 - Mount Holly, NJ “Treatment of Metastatic Colorectal Cancer.”
108. November, 2007 – New York, NY “A Case Based Approach to the Use of Avastin® in Metastatic Colorectal Cancer.”
109. November, 2007 - Endicott, NY “The Evolving Role of Targeted Therapy.”
110. December, 2007 – Philadelphia, PA “Breast Cancer Treatment for African-American Women.”
111. December, 2007 - Appleton, WI “Treatment of Metastatic Colorectal Cancer.”
112. December, 2007 – Philadelphia, PA “A Case Based Approach to the Use of Avastin® in Metastatic Colorectal Cancer.”
113. January, 2008 – Staten Island, NY “Treatment of Metastatic Colorectal Cancer.”
114. January, 2008 – Philadelphia, PA “The Management of Venous Thromboembolic Disease.”
115. January, 2008 – Edison, NJ “Treatment of Metastatic Colorectal Cancer.”
116. February, 2008 – West Chester, PA “The Evolving Role of Erbitux® in Metastatic Colorectal Cancer.”
117. February, 2008 – Wynnewood, PA “Vectibix Clinical Overview.”
118. February, 2008 – Philadelphia, PA “The Evolving Role of Targeted Therapy: Evidence Based Strategies in the Treatment of Colorectal Cancer.”
119. March, 2008 – Kalamazoo, MI “Advances in the Diagnosis and Management of Colorectal Cancer.”
120. March, 2008 – Cambridge, MD “The Evolving Role of Targeted Therapy: Evidence Based Strategies in the Treatment of Colorectal Cancer.”

121. Mach, 2008 – Pasadena, CA “Vectibix Clinical Overview.”
122. March, 2008 – Philadelphia PA “The Evolving Role of Targeted Therapy: Evidence Based Strategies in the Treatment of Colorectal Cancer.”
123. March, 2008 – Philadelphia, PA “Advances in Anticoagulation for the Management of Venous Thromboembolic Disease.”
124. March, 2008 – Philadelphia, PA “Advances in Hormonal Therapy for Breast Cancer.”
125. March, 2008 – Denver, CO “Vectibix Clinical Overview.”
126. April, 2008 - Sunny Isles Beach, FL “Therapeutic Advances in Gastrointestinal Malignancies.”
127. April, 2008 - Collegeville, PA “Advances in Anticoagulation for the Management of Venous Thromboembolic Disease.”
128. April, 2008 - Sunny Isles Beach, FL - “Evidence-based Strategies in the Treatment of Colorectal Cancer.”
129. April, 2008 - Sacramento, CA “Vectibix Clinical Overview.”
130. April, 2008 – San Francisco CA “Vectibix Clinical Overview.”
131. April, 2008 - Berkeley, CA “Vectibix Clinical Overview.”
132. April, 2008 – Bethlehem, PA “Vectibix Clinical Overview.”
133. April, 2008 – Philadelphia, PA “The Management and Treatment Options for Deep Vein Thrombosis.”
134. April, 2008 – Philadelphia, PA “Evidence-based Strategies in the Treatment of Colorectal Cancer.”
135. April, 2008 – Collegeville, PA “Disparities in the Incidence and Treatment of Colorectal Cancer.”
136. April, 2008 – Philadelphia, PA “Vectibix Clinical Overview.”
137. April, 2008 – Philadelphia, PA “The Role of Women as Clinical Research Participants.”
138. May, 2008 – Philadelphia, PA “Advances in the Treatment of Early Stage Breast Cancer.”
139. May, 2008 – New Orleans, LA “Evidence-based Strategies in the Treatment of Colorectal Cancer.”
140. May, 2008 - Atlanta, GA “Addressing Healthcare Disparities in Colorectal Cancer: Optimizing Therapeutic Outcomes in African-American Patients with Advanced or Metastatic Disease.”

141. May, 2008 – Detroit, MI - April, 2008 - Sacramento, CA “Vectibix Clinical Overview.”
142. May, 2008 – Pittsburgh, PA “The Management of Venous Thromboembolic Disease.”
143. May, 2008 – Philadelphia, PA “Vectibix Clinical Overview.”
144. May, 2008 – St. Maarten, Virgin Islands “Evidence-based Strategies in the Treatment of Colorectal Cancer.”
145. May, 2008 – Philadelphia, PA Conducted nine web-conference programs “Racial Differences in Cancer Care.”
146. June, 2008 - West Conshohocken, PA “Neuropathy: Causes and Strategies for Getting Relief.”
147. June, 2008 – Barcelona, Spain 2008 World Congress on Gastrointestinal Cancer
148. June, 2008 – Philadelphia, PA “Advances in Anticoagulation for the Management of Venous Thromboembolic Disease.”
149. July, 2008 - Philadelphia, PA “A Case Based Approach to the Use of Avastin® (Bevacizumab) in Metastatic Colorectal Cancer.”
150. July, 2008 – York, PA “Treatment Options in GI Cancers: Optimizing Outcomes.”
151. July, 2008 – Ridgewood, NJ “A Case Based Approach to the Use of Avastin® in Metastatic Colorectal Cancer.”
152. July, 2008 – Philadelphia, PA “The Evolving Role of Erbitux® (Cetuximab) in Metastatic Colorectal Cancer.”
153. August, 2008 – Washington, DC 7th International Congress on Targeted Therapies in Cancer
154. August, 2008 – Columbus, OH “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
155. August, 2008 – Philadelphia, PA “The Role of Erbitux® in Metastatic Colorectal Cancer.”
156. August, 2008 – San Francisco, CA “Vectibix Clinical Overview.”
157. August, 2008 – Berkeley, CA “Vectibix Clinical Overview.”
158. August, 2008 - Oakland, CA “Vectibix Clinical Overview.”
159. September, 2008 - Ridgewood, NJ “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
160. September, 2008 – Philadelphia PA “The Management and Treatment Options for Deep Vein Thrombosis.”

161. September, 2008 - Rolla, MO “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
162. September, 2008 – Cherry Hill, NJ “The Management and Treatment Options for Deep Vein Thrombosis.”
163. September, 2008 – Philadelphia, PA “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
164. September, 2008 - Louisville, KY “Disparities in the Incidence and Treatment of Colorectal Cancer.”
165. September, 2008 – Wilmington, DE “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
166. September, 2008 - Bethlehem, PA “Vectibix Clinical Overview.”
167. September, 2008 - Hamilton, NJ “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
168. October, 2008 – Burlington, VT “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
169. October, 2008 – Philadelphia, PA “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
170. October, 2008 - Syracuse, NY “Vectibix Clinical Overview.”
171. October, 2008 – 2008 Pennsylvania Breast Cancer Coalition Annual Conference; “Racial Disparities in Breast Cancer.”
172. October, 2008 – Bronx, NY “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
173. October, 2008 – Philadelphia, PA “The Management and Treatment Options for Deep Vein Thrombosis.”
174. October, 2008 - Seaford, DE “Treatment Options in Gastrointestinal Cancers: Optimizing Outcomes.”
175. October, 2008 – Philadelphia, PA “A Case Based Approach to the use of Avastin® in Metastatic Colorectal Cancer.”
176. November, 2008 – Bronx, NY “Targeting VEGF in Metastatic Colorectal Cancer: An Overview of Avastin® (bevacizumab)”
177. November, 2008 – Sydney Australia; Clinical Oncological Society of Australia 2008 Annual

Scientific Meeting “Disparities in Cancer Care”

178. December, 2008 – Philadelphia, PA “Advancing Treatment Paradigms with Targeted Therapies, Management of Colorectal Cancer”
179. December, 2008 – Philadelphia, PA “The Link Between Breast and Ovarian Cancers and the Importance of Clinical Trials”
180. January, 2009 - Cooperstown, NY “Vectibix Clinical Overview”
181. January, 2009 - Glens Falls, NY “Vectibix Clinical Overview”
182. January, 2009 - San Francisco, CA “Vectibix Clinical Overview”
183. January, 2009 – San Francisco, CA “Molecular Markers & Prognosis of Patients with Colorectal Cancer”
184. February, 2009 – Boston, MA “Vectibix Clinical Overview”
185. February, 2009 – Hyde Park, NY “Vectibix Clinical Overview”
186. February, 2009 – Philadelphia, PA “Vectibix Clinical Overview”
187. February, 2009 – Philadelphia, PA “Advancing Treatment: Paradigms with Targeted Therapies”
188. February, 2009 – Randallstown, MD “ACCP Evidence Based Guidelines and Factor Xa Inhibition in the Management of VTE
189. March, 2009 - Harrisburg, PA “Vectibix Clinical Overview
190. March, 2009 – Bridgeport, CT “Molecular Markers and Prognosis of Patients with Colorectal Cancer”
191. March, 2009 – Madison, WI “Vectibix Clinical Overview”
192. March, 2009 – Kansas City, MO “Current Trends in GI Malignancies”
193. March, 2009 – Lebanon, PA “Vectibix Clinical Overview”
194. April, 2009 - West Conshohocken, PA “Bone Mets: Standard and Novel Treatments”
195. April, 2009 – Harrisburg, PA “Vectibix Clinical Overview”
196. April, 2009 – York, PA “Vectibix Clinical Overview”
197. April, 2009 – Philadelphia, PA “Advances in the Treatment of Gastrointestinal Stromal Tumor (GIST)”

198. April, 2009 - Voorhees, NJ “Previstage GCC “
199. April, 2009 – Buffalo, NY “Targeting VEGF in MCRC: An Overview of Avastin”
200. April, 2009 – Nashville, TN “Targeted and Molecular Therapy in the Management of Colorectal Cancer”
201. April, 2009 – San Antonio, TX “EGFR Inhibitors and the Management of Skin Toxicities”
202. April, 2009 – Williamsville, NY “Targeting VEGF in MCRC: An Overview of Avastin”
203. April, 2009 – Philadelphia, PA “Advances in the Treatment of Gastrointestinal Stromal Tumor”
204. July, 2009 – Philadelphia, PA “The Management of Venous Thromboembolic Disease”
205. September, 2009 – Marmora, NJ “The Management of Venous Thromboembolic Disease”
206. September, 2009 –Beesley’s Point, NJ The Management of Venous Thromboembolic Disease”
207. October, 2009 –Philadelphia, PA “Update to Vectibix Clinical Overview”
208. January, 2010 –Williamsport, PA “Update to Vectibix Clinical Overview”
209. February, 2010 –Seattle, WA “Update to Vectibix Clinical Overview”
210. February, 2010 –Bremerton, WA “Update to Vectibix Clinical Overview”
211. February, 2010 –Tacoma, WA “Update to Vectibix Clinical Overview”
212. February, 2010 –Portland, OR “Update to Vectibix Clinical Overview”
213. February, 2010 – Philadelphia, PA “Update to Vectibix Clinical Overview”
214. February, 2010 – Hackensack, NJ “Update to Vectibix Clinical Overview”
215. February, 2010 –Hershey, PA “Update to Vectibix Clinical Overview”
216. March, 2010 – Little Rock, AK “Novel Treatments for Metastatic Colorectal Cancer”
217. March, 2010 –Binghamton, NY “Update to Vectibix Clinical Overview”
218. March, 2010 – Arlington, VA “Minority Participation in Cancer Research”
219. March, 2010 – Kansas City, MO “Current Trends in Gastrointestinal Malignancies”
220. April, 2010 – New York, NY “Update to Vectibix Clinical Overview”
221. April, 2010 – Philadelphia, PA “A Case Based Approach to the Use of Avastin® (bevacizumab) in”

Metastatic Colorectal Cancer”

222. April, 2010 – Sacramento, CA “Update to Vectibix Clinical Overview”
223. April, 2010 – Houston, TX “Over 40 vs. Under 40 Breast Cancer Screening, Diagnosis and Treatment”
224. April, 2010 – Berkeley, CA “Update to Vectibix Clinical Overview”
225. April, 2010 – Washington, DC National Minority Quality Health Disparities Forum
226. May, 2010 – Pittsburgh, PA Pancreatic Cancer Action Network Symposium
227. May, 2010 – Bethesda, MD “*Erbix* in the Treatment of Colorectal Cancer”
228. May, 2010 – Montego Bay, Jamaica “Colorectal Cancer in African Americans”
229. June, 2010 – New York, NY “Management of Patients with Colorectal Cancer”
230. September, 2010 – Philadelphia PA “The Important Role of Clinical Trials”
231. September, 2010 – West Orange, NJ “Targeted Therapy for Metastatic Colorectal Cancer”
232. September, 2010 – Salisbury, MD “Management of Patients with Colorectal Cancer”
233. October, 2010 – Philadelphia, PA “A Discussion on the Use of EGFR-Inhibitors in the Management of Patients with Metastatic Colorectal Cancer”
234. October, 2010 – Philadelphia, PA “*Erbix* in the Management of Patients with Colorectal Cancer”
235. October, 2010 – Lindenwold, NJ “Breast Cancer Awareness – A Celebration of You”
236. November, 2010 – Clayton, MO “A Discussion on the Use of EGFR-inhibitors in the Management of Patients with Metastatic Colorectal Cancer”
237. November, 2010 – Philadelphia, PA “Neuroendocrine Tumors: The Importance of Early Recognition”
238. November, 2010 – Pittsburgh, PA “A Case Based Approach to the Use of Avastin® (bevacizumab) in Metastatic Colorectal Cancer.”
239. November, 2010 – Miami, FL “Building Capacity to Address Cancer Health Disparities in Populations of African Descent.”
240. February, 2011 – Orlando, FL “Triple-Negative Breast Cancer: A Closer Look.”
241. April, 2011 – Philadelphia, PA “Grand Round Presentation on Liver Cancer.”

242. April, 2011 – Washington, DC “Cancer Biomarkers, Clinical Trials and New Treatment Options.”
243. May 2011 – Baton Rouge, LA “Exploring Triple Negative Breast Cancer.”
244. May 2011 – Philadelphia, PA “Insights and Treatment Strategies for Chemotherapy Induced Nausea and Vomiting.”
245. November, 2011 – New York, NY “Evaluating Emerging Targeted Therapies in the Management of Metastatic Colorectal Cancer.”
246. October 29 – 30, 2011 - Cambridge, MA 9th Annual International Angiogenesis Conference
247. November 9, 2011 – New York, NY “Evaluating Emerging Targeted Therapies in the Management of Metastatic Colorectal Cancer”
248. July 24, 2012 – Philadelphia, PA “Disparities in Colorectal Cancer: Predictive and Prognostic Factors”
249. July, 2012 – New Orleans, LA “Bridging Racial Disparities in Cancer Incidence and Outcomes.”
250. September 19, 2012 - Rock Island, IL “Colorectal Cancer Update.”
251. October 22, 2012 – Flemington, NJ “Colorectal Cancer Update.”
252. December, 2012 – New York, NY “Expert Practice in Colorectal Cancer: The Role of Antiangiogenic Therapy”
253. February, 2013 – Drexel Hill, PA “Update in Colorectal Cancer.”
254. March, 2013 – Little Rock, AK “Colorectal and GI Malignancies.”
255. July, 2013 – Washington, DC “Achieving New Standards in the Treatment of Breast Cancer: Nuances of Optimal, Individualized, Evidence-Based Patient Care.”
256. July, 2013 – Philadelphia, PA “Achieving New Standards in the Treatment of Breast Cancer: Nuances of Optimal, Individualized, Evidence-Based Patient Care.”
257. July, 2013 – Toronto, Ontario “Navigating the Complex World of Cancer Diagnosis and Care: How Can We Minimize Disparities?”
258. August, 2013 – Boston, MA “Targeted Therapies for Metastatic Colorectal Cancer: Expert Guidance for Clinicians.”
259. August, 2013 – Los Angeles, CA “Targeted Therapies for Metastatic Colorectal Cancer: Expert Guidance for Clinicians.”
260. August, 2013 – Denver, CO “Targeted Therapies for Metastatic Colorectal Cancer: Expert Guidance for Clinicians.”

261. September, 2013 – Hershey, PA “Achieving New Standards in the Treatment of Breast Cancer: Nuances of Optimal, Individualized, Evidence-Based Patient Care”
262. October, 2013 – Omaha, NE “Racial Disparities in Colon Cancer.”
263. October, 2013 – Denver, CO “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
264. October, 2013 – Philadelphia, PA “Understanding the Affordable Care Act in 2013: What’s New.”
265. October, 2013 – Seattle, WA “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
266. November, 2013 – St. Louis, MO “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
267. November, 2013 – Atlanta, GA “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
268. November, 2013 – Houston, TX “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
269. December, 2013 – Scranton, PA “Update on Colon Cancer”
270. December, 2013 – St. Louis, MO “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
271. January, 2014 – Tampa, FL “Unequal Treatment Revisited 10 Years After: Are we on the Right Path?”
272. March, 2014 – Philadelphia, PA “Disparities in Triple Negative Breast Cancer.”
273. April, 2014 – Columbus, OH “Addressing Disparities in Cancer Treatment.”
274. April, 2014 – Ft. Lauderdale, FL “Stomach Cancer Update: Management of Side Effects.”
275. May, 2014 – Scranton, PA “Update on Colon Cancer.”
276. August, 2014 – Honolulu, HI “Colon Cancer in 2014: Improved Survival.”
277. August, 2014 - Honolulu, HI “Triple Negative Breast Cancer: Triumphs and Challenges.”
278. September, 2014 – Cleveland, OH “Navigating the Complex World of Cancer Diagnosis and Care: Minimizing Disparities.”
279. September, 2014 - North Bergen, NJ “Modern Metastatic Colorectal Cancer Management: Expert Guidance for Individualized Care in the Community Setting.”

280. October, 2014 – Harrisburg, PA “Options for Triple-Negative Breast Cancer”
281. October, 2014 - Atlanta, GA “Current and Emerging Treatments in GIST
282. October, 2014 – Scranton, PA “Update on Colon Cancer.”
283. December, 2014 – St. Louis, MO “Expanding Targeted Therapeutic Options in Gastrointestinal Malignancies.”
284. December, 2014 – Philadelphia, PA “Understanding Triple Negative and Inflammatory Breast Cancer”
285. December, 2014 – Philadelphia, PA
286. March, 2015 – Philadelphia, PA “Understanding Triple Negative Breast Cancer, Metastatic Breast Cancer.” (Lecture given in Spanish)
287. April, 2015 – Philadelphia, PA “Addressing Disparities in Breast Cancer Treatment.”
288. June, 2015 – Hartford, CT “Innovation in Cancer Therapies.”
289. June, 2015 – Wilmington, DE “Medicare at Fifty Years: Impact on Health Care Disparities.”
290. August, 2015 – Detroit, MI “Disparities and Opportunities in Cancer Care: The Role of Non-Oncologists.”
291. September, 2015 – Washington, DC “Collective Leadership to Eliminate the Prostate Cancer Disparities.”
292. October, 2015 – Harrisburg, PA “Triple Negative Breast Cancer: How Can Outcomes Be Improved?”
293. October, 2015 – Philadelphia, PA “Racism in Medicine.”
294. February, 2016 – Philadelphia, PA “Medicare at Fifty Years: Impact on Health Care Disparities.”
295. February, 2016 – Tampa, FL “Health Disparities and Personalized Medicine.”
296. February, 2016 – Wilmington, DE St. Francis Hospital Grand Rounds
297. February, 2016 – Philadelphia, PA “Breast Cancer’s Impact on African-American Women.”
298. March, 2016 – Philadelphia, PA “Understanding Triple Negative Breast Cancer, Metastatic Breast Cancer.”
299. June, 2016 - Las Vegas, NV “Health Care Equity.”

300. June, 2016 – Baltimore, MD “Navigating the Complex World of Cancer Diagnosis and Care: Minimizing Disparities.”
301. June, 2016 – North Wales, PA “Addressing Disparities in Cancer Treatment.”
302. July, 2016 – Philadelphia, PA “Medicare at Fifty Years: Impact on Health Care Disparities.”
303. July, 2016 – Cincinnati, OH “Increasing Diversity in Clinical Trials.”
304. August, 2016 – Los Angeles, CA “Minorities and State of the Art Cancer Care.”
305. August, 2016 – Tunica, MS “Health Care for Our Communities: Building A New Future.”
306. September, 2016 – Philadelphia, PA “The Impact of Medicaid on Health Disparities: Access to Cancer Care.”
307. September, 2016 – Philadelphia, PA “Metastatic Breast Cancer in African Americans.”
308. September, 2016 - Washington, DC “Increasing African American Participation in Prostate Cancer Clinical Trials.”
309. September, 2016 - Ft. Lauderdale, FL “Launching Towards Equity: The Role of Young Investigators in the National Cancer Moonshot Initiative.”
310. September, 2016 - Ft. Lauderdale, FL “Cancer Moonshot: Blue Ribbon Panel Report 2016.”
311. September, 2016 - Washington, DC “Cancer Moonshot: Eliminating Cancer Disparities in the 21st Century.”
312. September, 2016 – Sarasota, FL “Navigating the Complex World of Cancer Diagnosis and Care; Minimizing Disparities.”
313. October, 2016 – Washington, DC “Equity in Clinical Trials.”
314. October, 2016 – Philadelphia, PA “The Impact of Medicaid on Health Disparities: Access to Cancer Care.”
315. October, 2016 - Farmington, CT “Living in America Today: Transforming Environments to Eliminate Health Disparities.”
316. October, 2016 – Philadelphia, PA (*Make the Change* Radio Broadcast) “Disparities in Breast Cancer Awareness, Prevention, Treatment and Survival.”
317. November, 2016 – Sarasota, FL “Medicare at Fifty Years: Impact on Health Care Disparities.”
318. November, 2016 – New York, NY “Embodying Black Female Physician Excellence.”
319. December, 2016 – New York, NY “2016 Moonshot: Potential Impact on Gastric Cancer.”

320. December, 2016 – Memphis, TN “Health Disparities in Cancer Care.”
321. February, 2017 – Ft. Washington, PA “Diversity of Experience and Thought.”
322. March, 2017 – Atlanta, GA “The Need for HIV Prevention in Diverse Populations: Eliminating Health Disparities.”
323. March, 2017 - Harrisburg, PA “Medicare at Fifty Years: Impact on Health Care Disparities.”
324. March, 2017 – Orlando, FL “Addressing Health Disparities in Cancer Care from Diagnosis to Survivorship.”
325. March, 2017 – Los Angeles, CA “Moonshot and the Impact on Disparities in Cancer.”
326. April, 2017 – Evansville, IN “Current and Emerging Mutation-based Treatment Strategies for Advanced Metastatic Colorectal Cancer.”
327. April, 2017 – Washington, DC “Primary Care: Promoting High-Quality, Longer Lives.”
328. April, 2017 – Atlanta, GA “Healthcare Systems Demystified: Medicaid and Medicare.”
329. April, 2017 – Newark, DE “The Cancer Moonshot Initiative and the Impact on Disparities in Cancer.”
330. May, 2017 – Philadelphia, PA “The Link Between Hepatitis and Liver Cancer; Challenges in Reaching At-Risk Populations.”
331. May, 2017 – Philadelphia, PA “Medicare at Fifty Years: Impact on Health Care Disparities.”
332. August, 2017 – Philadelphia, PA “Identifying and Correcting Disparities in Cancer Care for Minority Populations: The Importance of Participation by Non-Oncologists.”
333. January, 2018 – Philadelphia, PA “Does Research and/or Prevention Decrease Mortality Rates in Breast Cancer?”
334. March, 2018 – Philadelphia, PA “Panel Discussion: Colorectal Cancer.”
335. July, 2018 – Harrisburg, PA “2018 ASCO Meeting Highlights.”
336. July, 2018 – Chicago, IL “Inclusion of Diverse Patient Populations in Clinical Trials.”
337. August, 2018 – Orlando, FL “Improved Survival in Cancer but Continued Disparities: The Future with Precision Medicine Looking Through the Rearview Mirror.”
338. August, 2018 – Orlando, FL “Precision Oncology: Today and Tomorrow.”

339. September, 2018 – Memphis, TN “Breast Cancer in African Americans: Reducing Disparities in 2018.”
340. September 2018 - American Association for Cancer Research in conjunction with Biden Cancer Community Summit “The Future of Cancer Research.”
341. October, 2018 - Washington, DC “Addressing Precision Medicine Across Solid and Hematologic Malignancies.”
342. October, 2018 – Philadelphia, PA “Breast Cancer in African Americans: Reducing Disparities in 2018.”
343. November, 2018 – Harrisburg, PA “Establishing A Treatment Paradigm In Post-Gemcitabine Metastatic Pancreatic Cancer.”
344. November, 2018 – Houston, TX “Precision Medicine: Advancements in Metastatic Breast Cancer Research and Treatment.”
345. November, 2018 – New Orleans, LA “Cancer Health Disparities.”
346. November 2018 – Bryn Mawr, PA – Grand Rounds Presentation “Gastrointestinal Cancer Update.”
347. November, 2018 – Dallas, TX “Precision Medicine: Advancements in Metastatic Breast Cancer Research and Treatment.”
348. April, 2019 – Seattle, WA Panel Discussion - “Single Payer versus Multi-payer Healthcare.”
349. April 2019 - Indianapolis, IN “Improved Survival but Continued Disparities in Cancer: Planning the Future while Looking through the Rear View Mirror.”
350. April, 2019 – Philadelphia, PA “Beyond Medicine: Physician Careers in Public Health.”
351. April, 2019 – Philadelphia, PA “Advocacy and Activism: Health Policy and the Community Impact”
352. May 2019, Philadelphia, PA “Breast Cancer Awareness and Prevention in African American Women”
353. June, 2019, Nashville, TN “Update in Breast Cancer Screening: The Tomosynthesis Mammographic Imaging Screening Trial (TMIST)”
354. July, 2019 – New Orleans, LA “Cancer Care Disparities.”
355. July, 2019 - Honolulu, HI “Precision Oncology for the Primary Care Physician.”
356. July, 2019, New Orleans, LA “Update in Breast Cancer Screening: The Tomosynthesis Mammographic Imaging Screening Trial (TMIST)”
357. July, 2019, Hershey, PA “2019 ASCO Meeting Highlights.”

358. July, 2019 - Zanesville, OH “Establishing A Treatment Paradigm In Post-Gemcitabine Metastatic Pancreatic Cancer”
359. July, 2019 – Hazelton, PA “A Clinical Update in Gastroentero-Pancreatic Neuroendocrine Tumors and Carcinoid Syndrome”
360. September, 2019 - Middletown, NY” “Clinical Concepts in the Understanding of Neuroendocrine Tumors”
361. September, 2019 – New Orleans, LA “A Clinical Update in Gastroentero-Pancreatic Neuroendocrine Tumors and Carcinoid Syndrome”
362. September, 2019 – Arlington, VA “Applying Precision Medicine for Solid Tumors and Hematologic Malignancies in Federal and Public Health Settings.”
363. October, 2019 – Philadelphia, PA “Precision Oncology for the Treatment of Breast Cancer.”
364. October, 2019 - Roanoke Rapids, NC “Update in Breast Cancer Screening: The Tomosynthesis Mammographic Imaging Screening Trial (TMIST)”
365. October, 2019 – Harrisburg, PA “Precision Oncology for the Treatment of Breast Cancer.”
366. November, 2019 – Philadelphia, PA ““Precision Oncology for the Treatment of Breast Cancer.”
367. November, 2019 – Tucson, AZ “Improved Survival but Continued Disparities: Precision Oncology for the Future but Looking Through the Rear View Mirror.”
368. November, 2019 – Baltimore, MD “Applying Precision Medicine for Solid Tumors and Hematologic Malignancies in Federal and Public Health Settings.”
369. November, 2019 – Philadelphia, PA “The Latest in Genetics and Clinical Trials.”
370. November, 2019 – Philadelphia, PA “Pancreatic Cancer Updates and Clinical Applications in Patient Care.”
371. November, 2019 – Philadelphia, PA “Breast Cancer Disparities in African American Women.”
372. February, 2020 – Washington, DC “Under-representation of African Americans in Multiple Myeloma Clinical Trials.”
373. May 5, 2020, Virtual Panel Presentation – “Screening Recommendations during COVID-19.”
374. May 18, 2020, Virtual Panel Presentation – “Innovations in Colorectal Cancer Treatment: Emerging Treatments in Clinical Trials.”
375. May 22, 2020, Radio Webcast Presentation – “The Importance of Clinical Research in Communities of Color.”

376. June 3, 2020, Virtual Presentation - "Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials."
377. June 25, 2020, Virtual Presentation LGBT Health Workforce Conference - "Publishing in the Journal of the National Medical Association."
378. June 26, 2020, Virtual Panel Presentation ECOG-ACRIN Cancer Research Group "Racism and Health Disparities in Cancer Research."
379. July 22, 2020, Virtual Presentation - "Implementation of Germline Testing for Prostate Cancer."
380. August 19, 2020, Virtual Presentation – "The Path to Diversity in Clinical Research and Health Equity."
381. August 20, 2020, Virtual Panel Discussion - "Doctors on the Front Lines Exploring Social Determinants of Health."
382. September 9, 2020, Virtual Podcast Presentation - "Health Disparities and Health Equity in Cancer Care."
383. October 10, 2020, Virtual Panel Presentation – "Triple-Negative Breast Cancer and Racial Disparities."
384. October 12, 2020, Virtual Panel Presentation, 2020 AACI/CCAF Annual Meeting - "Hastening Progress Towards Cancer Care Equity."
385. October 14, 2020, Virtual Panel Presentation – "Innovation in Oncology Development."
386. October 16, 2020, Virtual Presentation – "Triple-Negative Breast Cancer and Racial Disparities."
387. October 21, 2020, Virtual Presentation – "Update: Breast Cancer Treatment and Racial Disparities."
388. October 26, 2020, Virtual Panel Presentation – "Triple-Negative Breast Cancer."
389. November 9, 2020, Virtual Presentation – "Improved Survival but Continued Disparities in Colorectal Cancer: Planning the Future with Precision Oncology but Assessing the Past through the Rear View Mirror."
390. January 21, 2021, Virtual Presentation – "Disparities in Breast Cancer Discovery and Care."
391. February 17, 2021, Virtual Presentation Panel Moderator – 2021 Mercy-Douglass Lectureship "Disparities in Cancer Incidence and Outcomes."
392. February 24, 2021, Virtual Presentation "Introduction to Health Equity and Racial Disparities in Cancer Care."
393. February 24, 2021, Virtual Presentation – "Health Issues in the African-American Community."

394. February 27, 2021, Virtual Presentation - "Health Disparities and Health Equity in Cancer Care."
395. March 12, 2021, Virtual Presentation – The Nurses Role in Early Stage Breast Cancer: A Focus on Genomic Assays."
396. March 24, 2021, Virtual Presentation Panelist - "Uplifting Black Female Voices in Medicine."
397. April 7, 2021, Virtual Presentation Panelist - "The Long Journey to Health Equity: A Candid Conversation about Public Health in Philadelphia."
398. April 9, 2021, Virtual Presentation - "The COVID Vaccine and Communities of Color."
399. April 14, 2021, Virtual Presentation Panelist – "Addressing Disparities in Cancer Care: GI Cancers."
400. April 19, 2021, Virtual Presentation– "Impact of Health Inequity on African Americans in Clinical Research."
401. April 21, 2021, Virtual Presentation– "Addressing Clinical Trial Enrollment Barriers in Unique Populations."
402. April 27, 2021, Virtual Presentation – "LGBTQIA Inclusion in Research Design."
403. April 29, 2021, Virtual Presentation – "Ensuring Equitable Care for Cancer Patients and Families during the COVID-19 Pandemic."
404. May 21, 2021, Virtual Presentation Fred Hutchinson Cancer Research Center – "Racial Justice and Health Equity and Community Engagement"
405. June 10, 2021, Virtual Presentation Panelist – "Equity, Health, and Resources for the LGBTQ+ Community."
406. June 17, 2021, Virtual Presentation – "Cancer Prevention, Personalized Medicine and Population Health."
407. June 18, 2021, Virtual Presentation Panelist – 22nd Annual Cancer Survivor and Thriver Day - "Treatment, Clinical Research and Survivorship."
408. June 21, 2021, Virtual Presentation – "How Health Care Disparities May Impact Your Cancer Treatment and Care."
409. June 26, 2021, Virtual Presentation – "Women's Health Across the Lifespan."
410. July 13, 2021, Virtual Presentation Panelist – "Planning the Future with Precision Medicine, but Assessing the Past through the Rear View Mirror."
411. July 20, 2021, Virtual Presentation Panelist – "Driving for Health Equity Through Early Screening Initiatives in Oncology."

412. July 21, 2021, Virtual Presentation Panelist - National Science Foundation and Stand Up to Cancer
413. July 23, 2021, Virtual Presentation – “Inclusive and Diverse Clinical Trials.”
414. August 11, 2021, Virtual Presentation – “Disparities in Prostate Cancer.”
415. September 8, 2021, Virtual Presentation – “Disparities in Lung Cancer.”
416. September 30, 2021, Virtual Presentation – “Staying the Course: Breast Health Disparities in the Era of COVID19.”
417. October 4, 2021, Virtual Presentation - Multidisciplinary Summit on Treating Advanced Prostate Cancer in the Community Setting – “Strategies to Improve Patient Care for Patients with Advanced Prostate Cancer.”
418. October 7, 2021, Virtual Presentation – “Pathway to Medical School.”
419. October 8, 2021, Virtual Presentation Panelist – “Forum on Clinical Trial Participation and Underrepresented Populations: Overcoming Barriers and Finding Solutions.” Presentation: Perspective of a Practicing Clinician and Her Patients.
420. October 14, 2021, Virtual Keynote Address – Tower Health Research Day
421. October 15, 2021, Virtual Presentation Panelist - Association for Value-Based Cancer Care Conference. Panel: “Disparities and the Impact on Cancer Care.”
422. October 16, 2021, Virtual Presentation – Sisters Network Inc., “The State of the Black Breast Cancer Crisis.”
423. October 20, 2021, Virtual Presentation – Black Health Matters - “A Candid Talk about Breast Cancer.”
424. October 23, 2021, Live Radio Broadcast - Black Health Matters - “A Candid Talk about Breast Cancer.”
425. November 6, 2021, Virtual Presentation – “Cancer Screening in Primary Care: Addressing Disparities and the Potential of Improving Outcomes Through the Use of Liquid Biopsy.”
426. November 8, 2021, Virtual Presentation, Pfizer Oncology Lecture Series - Improved Survival in Cancer but Continued Disparities: *Planning the Future With Precision Medicine, but Assessing the Past through the Rear View Mirror.*”
427. November 11, 2021, Veterans Day Virtual Presentation, Boston Legacy Foundation Release of *The Boston Adventures Comic Book.*
428. November 23, 2021, Virtual Presentation – “Recognizing the Benefits of Women in Health Care.”

429. January 3, 2022, Live Radio Broadcast – WURD Radio - “Preventive Cancer Screenings for Women and Communities of Color.”
430. January 14, 2022, SKCC Radiation Oncology Grand Rounds Speaker – “Healthcare Disparities in Cancer Care.”
431. January 14, 2022, Jack and Jill of America, Inc. Webinar Presentation – “Tools for Caregivers: A discussion for those caring for children, spouses, family members and others.”
432. January 17, 2022, Virtual Keynote Address, Sisters in Service Foundation/Alpha Kappa Alpha Sorority, Inc., Martin Luther King Event.
433. January 28, 2022, Aspiring Physician Executives Virtual Panel Presentation - “Impact Beyond Bedside: Stories in Leadership.”
434. February 2, 2022, Webinar Panel Presentation, 2022 Diversity in Cancer Care Clinical Practice, Research and Education - “Diversity in Clinical Practice.”
435. February 9, 2022, Virtual Panel Moderator, GRY Health – “Improving Representation of Diversity in Clinical Trials Through Academia and Community Collaboration.”
436. February 15, 2022, Virtual Lecture, Indiana Cancer Consortium Cancer Survivorship and Prevention ECHO Program, “Disparities in Cancer Care.”
437. February 16, 2022, Virtual Lecture, Pfizer Black History Month Presentation, “Improved Survival in Cancer but Continued Disparities: *Planning the Future With Precision Medicine, but Assessing the Past through the Rear View Mirror.*”
438. February 23, 2022, Webinar Panel Presentation, *The Cancer Letter*, “The Evolution of the Health Equity Movement: Black History Month Panel.”
439. February 24, 2022, Webinar Panel Presentation, NMA Cobb Institute and Dana Farber Cancer Institute - “Participation in Research: Researching a Cure for Multiple Myeloma.”
440. February 24, 2022, SNMA Black History Month Lecture, “African Americans in Medicine.”
441. March 1, 2022, Virtual Panel Presentation, Black Health Matters - “Historic Mistrust of the Medical Field and Pharmaceutical Industry in the Black Community.”
442. March 4, 2022, Virtual Keynote Address, SUNY Downstate Health Sciences University 7th Annual Cancer Health Disparity - “Improved Survival in Cancer but Continued Disparities: *Planning the Future With Precision Medicine, but Assessing the Past through the Rear View Mirror.*”
443. March 7, 2022, Virtual Lecture, Sema4 - “Disparities in Colorectal Cancer.”
444. March 11, 2022, Virtual Panel Presentation, Colorectal Cancer Alliance – “Health Equity in Colorectal Cancer.”

445. March 14, 2022, Live Radio Broadcast, WURD Radio – “Disparities in Colorectal Cancer.”
446. March 21, 2022, Podcast Recording, Sema4 – “Colorectal Cancer and Disparity in Precision Oncology.”
447. March 27 2022, Panel Presentation, National Medical Association Colloquium on African American Health - “Advances and Innovations in Sickle Cell Disease and Beyond.”